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 Objective 
This report describes medication 
therapy at visits to physician offices, 
hospital outpatient departments, and 
emergency departments in the United 
States during 2003 and 2004. 
Office-based care is further subdivided 
into three categories—primary care, 
surgical specialties, and medical 
specialties. 
Methods 
Data from the 2003 and 2004 
National Ambulatory Medical Care 
Surveys (NAMCS) and National 
Hospital Ambulatory Medical Care 
Surveys (NHAMCS) were combined to 
produce averaged annual estimates of 
ambulatory medical care utilization. 
Results 
An estimated 1.9 billion drugs per 
year were provided, prescribed, or 
continued at ambulatory care visits in 
the United States during 2003 and 
2004. Two-thirds of the 1.1 billion 
ambulatory care visits per year included
medication therapy. The rate was 
highest at visits to medical specialists 
(2.3 drugs per visit). The rate of drugs 
per visit increased with patient age in 
each ambulatory care setting. 
Cardiovascular-renal was the class 
of drugs most frequently cited at visits 
to primary care physicians and medical
specialists. Pain relievers were the 
drugs reported most often at hospital 
emergency and outpatient department 
visits. Of the 50 drugs most frequently 
reported overall, three-quarters of them
were accounted for by six therapeutic 
classes—pain relievers, cardiovascular
renal agents, respiratory tract drugs, 
central nervous system drugs 
(antianxiety agents and 
antidepressants), hormonal agents, and
antimicrobials. Ibuprofen, aspirin, 
atorvastatin calcium, acetaminophen, 
and albuterol were the five most 
frequently reported medications. From 
1993 to 2004, the number of drugs 
provided, prescribed, or continued per 
visit increased for all settings. 
Keywords: ambulatory care visits c 
drug mentions c medication therapy c 
pharmacotherapy c therapeutic 
classification Medication Therapy in 
Ambulatory Medical Care: 
United States, 2003–04 
by Saeid Raofi, M.S., and Susan M. Schappert, M.A., 
Division of Health Care Statistics Introduction 
Medication therapy, or pharmacotherapy, is the predominant treatment 
modality at ambulatory medical care 
visits, and the cost of this treatment has 
increased rapidly over the last decade. 
In 2003, prescription drug expenditures 
in the United States totaled $216.4 
billion, an increase of $22.4 billion from 
the previous year. The rate of increase 
exceeded 10 percent in 2001, 2002, and 
2003 (1). With such growth, an 
assessment of the volume and 
characteristics associated with 
medication therapy at ambulatory health 
care visits in the United States becomes 
especially important. 
This report describes medication 
therapy at ambulatory medical care 
visits in the United States across five 
ambulatory care settings—primary care 
offices, surgical specialty offices, 
medical specialty offices, hospital 
outpatient departments, and hospital 
emergency departments. The data 
presented are from the 2003 and 2004 
National Ambulatory Medical Care 
Surveys (NAMCS) and National 
Hospital Ambulatory Medical Care 
Surveys (NHAMCS), which were 
combined to produce averaged annual 
estimates of pharmacotherapy at 
ambulatory medical care visits in the 
United States. These surveys comprise 
the ambulatory care component of the 
National Health Care Surveys (NHCS), 
conducted by the Centers for Disease 
Control and Prevention’s National 
Center for Health Statistics. NHCS 
measures health care utilization across a variety of health care providers. More 
information can be found at 
www.cdc.gov/nchs/nhcs.htm. 
The report presents summary 
statistics based on selected data items 
common to NAMCS and NHAMCS, all 
of which are related to medication 
therapy. The annual summaries (2–7) 
and the forthcoming series report focus 
on general utilization data for 2003–04 
(8) and contain an overview of the 
medical care provided in each setting as 
well as some general findings on 
medication therapy. This report provides 
greater detail on medication therapy 
both within settings and across the 
spectrum of ambulatory health care as a 
whole. 
Methods 
This study is a secondary analysis of data collected in the 2003 and 2004 NAMCS and NHAMCS. 
The target universe for NAMCS 
includes visits made in the United States 
to the offices of nonfederally employed 
physicians (excluding those in the 
specialties of anesthesiology, pathology, 
and radiology) who were classified by 
the American Medical Association 
(AMA) or the American Osteopathic 
Association (AOA) as being primarily 
engaged in office-based patient care. 
Visits to private, nonhospital-based 
clinics and health maintenance 
organizations (HMOs) were within the 
scope of the survey, but those that 
occurred in federally operated facilities 
and hospital-based outpatient 
departments (OPD) were not. Telephone 
contacts and visits made outside the Page 1 
Page 2 [ Series 13, No. 163 ambulatory care setting were not 
sampled in either survey, although 
limited information on the numbers of 
such contacts was collected in NAMCS. 
The target universe for NHAMCS is 
in-person visits made to the OPDs and 
emergency departments (EDs) of 
nonfederal, short-stay hospitals 
(hospitals with an average stay of less 
than 30 days) or those whose specialty 
is general (medical or surgical) or 
children’s general, in the United States. 
Only OPDs under the supervision of a 
physician were within the scope of 
NHAMCS. Clinics specializing in 
ancillary services, treatment only (e.g., 
chemotherapy, dialysis, radiation, 
physical therapy), and ambulatory 
surgery were all out-of-scope for 
NHAMCS. Visits from sampled OPD 
clinics were combined to provide total 
estimates for OPD utilization. This 
includes clinics defined as general 
medical care (57.8 percent of the 
2003–04 total), pediatrics (14.0 percent), 
general surgery (11.6 percent), obstetrics 
and gynecology (8.2 percent), and all 
other types (8.4 percent). (Surgery 
clinics differ from ambulatory surgical 
centers in OPDs in that the former 
involve visits to surgeons for diagnosis 
of problems requiring surgery and for 
postsurgery followup. Ambulatory 
surgery centers provide surgical 
procedures that do not require 
hospitalization.) EDs were defined as 
those providing 24-hour emergency care. 
Emergency care clinics that were open 
less than 24 hours per day were 
considered as part of the OPD. 
The sampling frame for NHAMCS 
is based on hospitals that were listed in 
the April 1991 SMG Hospital Database. 
The original sample has been updated 
over the years to allow for inclusion of 
hospitals that opened or whose 
eligibility status had changed. The 2003 
NHAMCS sampling frame was updated 
using products of Verispan L.L.C., 
specifically, the ‘‘Healthcare Market 
Index’’ and ‘‘Hospital Market Profiling 
Solution.’’ These products were formerly 
known as the SMG Hospital Database 
and will be referred to as the Verispan 
Hospital Database (VHD). For the 2003 
NHAMCS only, an additional sample of 
66 hospitals (identified as having an ED 
and either located in nonmetropolitan statistical areas or under proprietary 
ownership) was selected from the 2002 
VHD to provide more reliable estimates 
for those categories. The 2004 
NHAMCS frame was updated using the 
2003 VHD. 
A multistage probability sample 
design is used in both surveys; the 
designs are described elsewhere (9,10). 
The combined 2003 and 2004 NAMCS 
dataset contains 50,514 encounter 
records from 2,779 in-scope physicians; 
the combined NHAMCS dataset 
contains 76,842 ED records and 66,275 
OPD encounter forms from 428 
participating hospitals in 2003 and 376 
in 2004. Response rates for both surveys 
ranged between 65 and 89 percent 
across the 2-year period. See Appendix I 
for additional information. 
Because the estimates presented are 
based on a sample rather than on the 
entire universe of ambulatory visits, they 
are subject to sampling variability. The 
‘‘Technical Notes’’ in Appendix I 
include an explanation of sampling 
errors and guidelines for judging the 
precision of the estimates, as well as 
information on the tests of significance 
used to establish differences among 
survey estimates. Unless otherwise 
noted, the determination of statistical 
significance was based on the two-tailed 
t-test. The Bonferonni inequality was 
used to establish the critical value for 
statistically significant differences (0.05 
level of significance) based on the 
number of possible comparisons within 
a particular variable (or variables) of 
interest. 
Encounter data for each sampled 
visit are collected using a one-page 
questionnaire, the Patient Record form 
(PRF). These forms are produced in 
three different versions that have been 
carefully designed for use in each 
survey setting—physician offices 
(NAMCS), and OPDs and EDs 
(NHAMCS)—but which contain many 
data items in common. NAMCS and 
OPD PRFs are nearly identical, but the 
ED PRF differs in ways appropriate to 
that setting. These forms are used by 
medical staff to record information 
about patient visits. Definitions of terms 
relating to the survey items are found in 
Appendix II. The PRFs are shown in 
Appendix III and should serve as a reference for readers as they review the 
survey findings presented in this 
document. 
In 2003 and 2004, pharmacotherapy 
data were collected in item 9, 
‘‘Medications & Injections’’ of the PRF, 
and the same format was used in all 
three settings. The question asks 
respondents to list up to eight ‘‘Rx and 
OTC medications, immunizations, 
allergy shots, anesthetics, and dietary 
supplements that were ordered, supplied, 
administered, or continued during this 
visit.’’ (Note: Rx is prescription; OTC is 
over the counter.) Each entry of a 
medication on the form is referred to as 
a ‘‘drug mention’’ in NAMCS and 
NHAMCS reports, and visits with at 
least one drug mention are termed 
‘‘drug visits.’’ The term, ‘‘prescribed,’’ 
as used in this report reflects the 
broader definition stated above. 
Drug mentions were coded 
according to a coding system developed 
at NCHS. A report describing the 
method and instruments used to collect 
and process drug information is 
available (11). Additional sources, 
including the American Drug Index, 
Drug Topics Red Book, Facts and 
Comparisons, and the National Drug 
Code Directory, 1995 edition (NDC), 
were used to identify and assign drug 
characteristics for analytical purposes 
(12–15). The NDC assigns therapeutic 
classes for each drug using a two-tiered 
system. There are 21 broad therapeutic 
classes (2-digit level), and drugs are 
assigned to subclasses (4-digit level) 
within the broad classes. This report 
presents therapeutic classes using the 2­
and 4-digit levels, depending upon the 
table. 
The presentation of drug mentions 
in terms of their generic substances has 
been changed for 2003–04 compared 
with previous years of NAMCS and 
NHAMCS reports. In the past, 
frequency of mention estimates 
combined single-ingredient agents with 
mentions of the agent as an ingredient 
in a combination drug. That is, a 
preparation containing acetaminophen 
and codeine was included both in the 
count for acetaminophen and the count 
for codeine in tables of drugs by their 
generic components. This meant that it 
was possible for the number of generic 
Series 13, No. 163 [ Page 3 substances to exceed the number of 
actual drug mentions. For this report 
(with the exception of Figure 5, which 
presents generic substances according to 
the method just described), drugs 
containing multiple ingredients are 
presented in tables of generic substances 
using entries that reflect combinations of 
ingredients. These entries are termed 
‘‘generic equivalents’’ in the text. For 
example, a preparation containing only 
acetaminophen and codeine would no 
longer be listed under each separate 
ingredient, but would appear in the table 
under a new entry for ‘‘acetaminophen 
with codeine.’’ 
Also of note is the fact that, since 
2002, up to three therapeutic classes can 
be coded for each drug mention in 
NAMCS and NHAMCS data. Therefore, 
summary statistics in tables that show 
mentions by therapeutic class of drugs 
can exceed the total number of drug 
mentions. 
Table 11 compares the drugs most 
frequently provided, prescribed, or 
continued at NAMCS and NHAMCS 
visits in 1993–94 with those in 
2003–04. It should be noted that, 
because only five drugs could be coded 
per visit during 1993–94, only the first 
five (out of a possible eight) drugs listed 
on the visit records for 2003–04 were 
used for the time comparison. 
Additional information about the 
analysis and presentation of drug 
estimates is shown in Appendix I. 
The PRF item, ‘‘Primary expected 
source of payment for this visit,’’ is 
used to define the method of payment 
expected by the provider for the visit. It 
includes the categories of private 
insurance, Medicare, Medicaid, Worker’s 
Compensation, self-pay, no charge, 
other, and unknown. For this report, 
self-pay and no charge were combined 
to yield estimates of uninsured visits. 
Worker’s Compensation, other, and 
unknown response categories were 
combined into a residual category called 
‘‘Other.’’ Visit rates by expected pay 
source use population estimates of 
health insurance from the 2003–04 
National Health Interview Surveys for 
the denominator (16,17). The numerator 
used in calculating rates for the 
no-insurance group comes from the PRF self-pay and no charge categories. 
Although not all uninsured visits are 
made by uninsured persons, the number 
of uninsured persons is used to calculate 
rates of uninsured visits. For NAMCS 
and NHAMCS self-pay and no charge 
visits (uninsured visits), there is no 
expectation of third-party payers 
covering the cost. 
Visits to office-based physicians, 
which account for 82 percent of the 
ambulatory care visits discussed in this 
report, were divided into three settings. 
This classification was suggested by the 
American Medical Association (18) and 
is based on physicians’ self-designated 
practice specialty to better portray the 
diversity of care that occurs in physician 
offices. Table I in Appendix I shows the 
specialties used to define each category. 
Self-designated practice specialty is 
collected from AMA and AOA as part 
of the initial sampling process and is 
confirmed with the physician at the time 
of the survey induction interview. For 
tabulation purposes, doctors of 
osteopathy were grouped with doctors of 
medicine according to specialty. 
In this report, the terms, ‘‘visits to 
office-based physicians’’ and ‘‘visits to 
physician offices’’ are used 
interchangeably, as are the terms ‘‘visits 
to specialists,’’ ‘‘visits to specialty 
offices,’’ and ‘‘visits to specialties.’’ 
Some tables in this report present 
data on population-based rates of drug 
mentions at ambulatory care visits. With 
the exception of the expected source of 
payment, the population figures used in 
calculating these rates were special 
tabulations of the civilian 
noninstitutionalized population of the 
United States, developed by the 
Population Division, U.S. Census 
Bureau, from the July 1, 2003, and July 
1, 2004, set of state population estimates 
by age, sex, race, and Hispanic origin. 
These estimates are based on census 
2000 data. Population figures are shown 
in Tables II and III in Appendix I. 
The U.S. Census Bureau was 
responsible for data collection for both 
surveys. Constella Group, formerly 
Analytic Sciences, Inc., Durham, North 
Carolina, performed processing 
operations and medical coding. As part 
of the quality assurance procedure, a 10 percent quality control sample of 
survey records was independently 
processed. Error rates (which include 
coding and keying) ranged between 0.0 
and 1.5 percent depending on the survey 
and item. 
Results 
This report contains detailed data on medication therapy at ambulatory care visits by setting 
type (Table 1), patient and provider 
characteristics (Tables 2,3), drug 
characteristics (Tables 4–7), ranked 
generic substances (Tables 8,9) and 
population-based prescribing rates for 
therapeutic classes of drugs 
(Tables 10,11). To examine changes over 
time, comparisons of generic substances 
used in 1993–94 and 2003–04 are 
presented in Table 12. Highlights of 
information found in the tables are 
shown below. 
Patient and Provider 
Characteristics 
There was an annual average of 1.1 
billion ambulatory care visits in 2003 
and 2004. Primary care offices 
accounted for the largest share 
(48.0 percent of visits), followed by 
medical specialty offices (17.6 percent) 
and surgical specialty offices 
(16.2 percent). About 10 percent of visits 
were made to hospital emergency 
departments, and 8.1 percent were made 
to hospital OPDs (Figure 1). Two-thirds 
of ambulatory care visits (66.4 percent) 
included medication therapy (Table 1). 
There were an estimated 1.9 billion 
drug mentions per year in 2003 and 
2004. One-half (50.1 percent) of all drug 
mentions were accounted for by visits to 
primary care physicians. Although 
surgical specialties accounted for 
16.2 percent of the visits, these visits 
only accounted for 7.6 percent of total 
drug mentions. In contrast, medical 
specialty offices accounted for 
17.6 percent of visits, but 22.9 percent 
of drug mentions. Visits to hospital EDs 
were responsible for 11.0 percent and 
OPDs were responsible for 8.4 percent 
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Figure 2. Average rate of drug mentions at ambulatory care visits by setting type, 
according to patient age: United States, 2003–04 of the total drug mentions (Table 2, 
Figure 1). 
As shown in Table 3, the average 
number of drug mentions per 100 visits 
was not significantly different at visits 
to primary care offices, OPDs, and EDs, 
ranging between 183.0 and 190.9 
mentions per 100 visits. The rate was 
higher for visits to medical specialty 
offices (227.7 drugs per 100 visits) 
compared with primary care office 
visits, but lower for surgical specialty 
visits (82.4 drugs per 100 visits). 
Drug mention rates (i.e., the number 
of drug mentions per 100 visits) 
increased in general with patient age, 
both overall and within each ambulatory 
care setting. The overall rate ranged 
from 126.4 drugs per 100 visits by 
patients under 15 years of age to 251.5 
drugs per 100 visits by patients 75 years 
and over (Figure 2). Drug mention rates 
for males and females were not 
significantly different, with one 
exception. The drug mention rate was 
higher for females (196.6 per 100 visits) 
than males (184.1 per 100 visits) at ED 
visits. 
There were no significant 
differences in drug mention rates by 
race. However, at visits to medical 
specialties, black patients had a higher 
likelihood of receiving one or more drugs (78.8 percent) than white patients 
(72.6 percent) or Asian patients (72.1 percent). These differences were 
statistically significant (X2 = 7.26, 
Series 13, No. 163 [ Page 5 p < 0.03) (Figure 3). There were no 
significant differences in drug mention 
rates by setting for Hispanic and 
non-Hispanic persons. 
The number of medications 
mentioned per 100 visits was 
significantly higher for visits where 
Medicare was the primary expected 
source of payment regardless of setting, 
reflecting the age of the Medicare 
population. In the medical specialty 
setting, uninsured visits had a lower rate 
of drug mentions (155.2 mentions per 
100 visits) compared with private 
insurance (205.4 mentions per 100 
visits) and Medicaid visits (230.8 
mentions per 100 visits). The rate was 
not significantly different for private 
insurance visits compared with Medicaid 
visits. 
Overall, there were no statistically 
significant differences in drug mention 
rates by geographic region. However, 
surgical specialty visits in the West had 
a higher drug mention rate (116.6 
mentions per 100 visits) than such visits 0 
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Figure 3. Percentage of ambulatory care visit
provided, or continued by patient race and sein other regions. ED visits in the West 
had a higher drug mention rate (220.7 
mentions per 100 visits) than in either 
the Northeast or the Midwest. 
With the exception of visits to 
primary care physicians, there were no 
significant differences in drug mention 
rates by setting for metropolitan 
statistical areas (MSAs) and 
nonmetropolitan statistical areas 
(non-MSAs). In non-MSAs, the drug 
mention rate at visits to primary care 
physicians was 213.3 mentions per 100 
visits compared with a rate of 177.7 
mentions per 100 visits in MSAs. 
Drug Characteristics 
As shown in Table 4, the majority 
(82.7 percent) of medications reported at 
ambulatory care visits were prescription 
drugs. Nonprescription preparations 
accounted for 9.8 percent of mentions 
overall, and 7.5 percent were of 
undetermined status. Mentions of 
nonprescription products and products of AsianBlackWhite 
Emergency 
departments 
Outpatient 
departments 
Medical 
pecialty
1 
offices 
are not shown because of small sample sizes. 
s with one or more medications prescribed, 
tting type: United States, 2003–04 undetermined status were higher at visits 
to EDs than at all other settings. The 
former finding is likely related to the 
frequent utilization at ED visits of 
nonprescription pain relievers such as 
acetaminophen, and the latter finding 
may be related to the frequent utilization 
of ibuprofen, which, in itself, can be 
used in either an over-the-counter or 
prescription strength. NAMCS and 
NHAMCS do not collect route, dosage, 
or regimen for medications listed on the 
PRF, so those drugs that can take either 
form (over the counter or prescription) 
cannot be classified. 
Table 4 also provides information 
on federal control status. The Controlled 
Substances Act, Title II of the 
Comprehensive Drug Abuse Prevention 
and Control Act of 1970, placed all 
substances that are regulated under 
existing federal law into one of five 
schedules, based on the substance’s 
medicinal value, harmfulness, and 
potential for abuse or addiction. 
Schedule I is reserved for the most 
dangerous drugs that have no currently 
accepted medical use in treatment in the 
United States. Schedule II-V drugs all 
have a currently accepted medical use 
and decreasing potentials for abuse and 
addiction, ranging from high (Schedule 
II) to low (Schedule V). See Appendix 
II for details. 
Schedule II and III drugs accounted 
for 4.5 percent of drug mentions overall. 
ED visits included a significantly higher 
proportion of schedule II drugs 
(7.0 percent) and schedule III drugs 
(6.3 percent) compared with all other 
settings. This is probably related to the 
preponderance of pain-relieving agents, 
including narcotic analgesics. Schedule 
IV drugs constituted 4.4 percent of drug 
mentions in the medical specialty 
setting. This was significantly higher 
than the percentages in other settings, 
which ranged from 2.4 to 3.4 percent. 
Therapeutic class of drugs by 
setting is shown in Table 5, using broad 
classes (2-digit level of the NDC). 
Cardiovascular-renal drugs had the 
highest rate of utilization at medical 
specialty offices with 37.4 occurrences 
per 100 visits. This was significantly 
higher than the rate for all other 
settings, with the exception of primary 
care offices (28.9 occurrences per 100 
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 visits). Pain relievers were utilized most 
often at ED visits (64.7 occurrences per 
100 visits), which was significantly 
higher than the rate for all other 
settings. 
The top 10 broad therapeutic classes
(2-digit level of the NDC) are shown for
ambulatory care visits, in general, in 
Figure 4. Eight of these classes are 
among the top 10 therapeutic classes for 
each setting (Table 6). These include 
cardiovascular-renal, pain relief, 
respiratory tract, central nervous system, 
metabolic and nutrient agents, hormones 
and hormonal agents, antimicrobials, 
and gastrointestinal agents. Opthalmics 
were among the top 10 at surgical 
specialty visits, and otics were among 
the top 10 at ED visits. Skin and 
mucous membrane drugs were ranked 
among the top 10 at each type of 
physician office visit (primary care, 
surgical specialty, and medical 
specialty). Neurologics appeared among 
the top 10 at medical specialty visits as 
well as at OPD and ED visits. More 
detailed data on therapeutic class of 
drug mentions are shown in Table 7, 
using the 4-digit therapeutic class codes 
from the NDC. Nonsteroidal anti­
inflammatory drugs (NSAIDs) (57.5 
mentions per 1,000 drug mentions) and NOTE: Based on the standard drug classification used in the
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Figure 4. Annual rates of occurrence of the t
provided, prescribed, or continued at ambulaantidepressants (45.8 mentions per 1,000 
drug mentions) were the top two 
specific drug classes prescribed. 
Figure 5 shows the 10 most 
frequently occurring generic substances 
in medications provided, prescribed, or 
continued at ambulatory care visits 
across all settings. As described 
previously, occurrence, in this figure 
only, is calculated as the sum of 
mentions of single-ingredient agents 
with mentions of the agent as an 
ingredient in a combination drug. 
Acetaminophen was the substance found 
most frequently, with 91.1 million 
mentions, reflecting 4.7 percent of total 
drug mentions. 
Drug mentions at ambulatory care 
visits overall are shown by ranked 
generic-equivalent substances in Table 8. 
As noted earlier, this method produces 
one generic-equivalent entry for each 
drug and can be aggregated to the total 
number of drug mentions. Ibuprofen was 
the most frequently used substance 
(2.1 percent of drug mentions), followed 
by aspirin (2.0 percent) and atorvastatin 
calcium (1.7 percent). When comparing 
results from this table with those in 
Figure 5, readers should note the 
difference in methods used, which will 
produce different results. For example,  National Drug Code Directory, 1995 edition (12). 
10 15 20 25 30 
ber of occurrences per 100 visits 
op 10 broad therapeutic classes of drugs 
tory care visits: United States, 2003–04 acetaminophen, when counted under its 
use as both a single-ingredient drug and 
a combination product, dominates the 
list of most frequently occurring generic 
substances in Figure 5, with an estimate 
of 91.5 million, or 4.7 percent of all 
drug mentions. When compared with 
results from Table 8, readers will note 
that acetaminophen as a single-
ingredient preparation accounts for 
1.6 percent of total drug mentions. The 
difference is related to the fact that 
acetaminophen is often prescribed as 
part of a combination product, and such 
products (e.g., acetaminophen with 
hydrocodone) are shown as separate 
entries in Table 8. 
The top 50 drugs were dominated 
by six therapeutic classes, using the 
2-digit NDC categories. These include 
pain relievers (9 drugs in the top 50), 
cardiovascular-renal drugs (6 drugs), 
respiratory tract drugs (6 drugs), central 
nervous system (6 drugs), hormones (6 
drugs), and antimicrobials (5 drugs). 
Albuterol was the most frequently 
mentioned respiratory tract drug and 
accounted for 1.5 percent of mentions 
overall. Sertraline, used in the treatment 
of depression and anxiety, was the most 
frequently mentioned central nervous 
system drug. Amoxicillin was the most 
frequently mentioned antimicrobial drug 
(1.3 percent of mentions), and 
furosemide was the most frequently 
mentioned cardiovascular agent. In the 
hormonal class, levothyroxine was 
mentioned most frequently, and 
ibuprofen was the most frequently 
mentioned pain reliever. Gastrointestinal 
agents and metabolics and nutrients 
were other classes with more than one 
drug among the top 50. 
Due to the diversity of vitamin 
products and lack of accurate 
information on the specific components 
of many multivitamins, they were 
excluded from Tables 8 and 9. This 
group, as a whole, accounted for 49.8 
million drug mentions (2.6 percent of all 
drug mentions) across all settings in 
2003–04. 
Table 9 presents the top 10 drugs in 
terms of their generic composition for 
each ambulatory care setting. In 
2003–04, the top three drugs cited at 
visits to primary care physicians were 
atorvastatin calcium (a cholesterol 
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Figure 5. Annual number of the 10 most frequently occurring generic substances in drugs 
provided, prescribed, or continued at ambulatory care visits: United States, 2003–04 
 
 
 lowering agent), aspirin, and 
amoxicillin. Among the top 10 drugs at 
visits to primary care physicians were 
three cardiovascular agents, three pain 
relievers, and two antibiotics. Albuterol, 
used in the control of asthma, and 
levothyroxine, used to treat thyroid 
disorders, were also present. 
At visits to surgical specialists, 
among the top 10 generic substances 
were five pain relievers, three 
ophthalmic agents, and two anesthetic 
drugs. Prednisolone, acetaminophen with 
hydrocodone, and latanprost, a glaucoma 
medication, were listed most frequently. 
Cardiovascular-renal drugs were 
prominent at visits to medical specialty 
offices, constituting 5 of the top 10 
drugs in that setting. Aspirin was the 
drug cited most frequently, and it 
accounted for 2.7 percent of mentions. 
Although it is classified in the NDC as 
a nonnarcotic analgesic, aspirin therapy 
is increasingly being used for the 
prevention and management of heart 
disease. 
Pain relief agents, cardiovascular 
drugs, antibiotics, and an asthma 
medication were all among the top 10 
drugs at OPD visits. Among the pain 
relievers, a narcotic analgesic, 
acetaminophen with hydrocodone, was also present. At ED visits, pain relievers
dominated with 6 of the top 10 drugs; 
acetaminophen with hydrocodone 
accounted for 5.2 percent of mentions. 
Taken together, the six pain relievers 
account for 24.3 percent, or one-quarter 
of ED drug mentions. Antibiotics, 
cardiovascular drugs, and asthma 
medication rounded out the list. 
Table 10 presents population-based 
prescribing rates for therapeutic classes 
(using the more detailed 4-digit NDC 
categories) of drugs provided, prescribed
or continued at ambulatory care visits 
by patient age and sex. Occurrence rates
for each of the 20 most commonly 
prescribed therapeutic classes of drugs 
increased with patient age, with the 
exception of vaccines and antisera. The 
rates for antidepressants and for 
vitamins and minerals for females were 
significantly higher than corresponding 
rates for males. 
Table 11 presents population-based 
prescribing rates for therapeutic classes 
of drugs by patient race, expected 
source of payment for the visit, and 
MSA status. White persons had a much 
higher rate of antidepressant mentions 
than black persons, and black persons 
had a higher rate of blood glucose 
regulators. Persons whose expected source of payment was Medicaid had 
the highest rate of penicillin mentions 
compared with those who had other 
payment sources. Those defined as 
uninsured had the lowest rate for all of 
the top 20 therapeutic classes with the 
exception of antidepressants, narcotic 
analgesics, nonnarcotic analgesics, and 
anticonvulsants. The mention rate for 
vaccines was higher in MSAs than 
non-MSAs. 
Time Comparisons 
To look at changes over time, drug 
mention rates (number of mentions per 
100 visits) for each ambulatory care 
setting are compared for 1993–94 and 
2003–04 in Figure 6. Because only five 
drugs could be reported in 1993 and 
1994, the number of drugs analyzed for 
2003–04 in this figure only reflects the 
first five listed on the PRF. In addition, 
data for both sets of years reflect the 
generic-equivalent method for displaying 
drug data described in the ‘‘Methods’’ 
section. Rates were higher for all 
settings in 2003–04 compared with 
1993–94. 
Further comparisons are shown in 
Table 12, with the most frequently 
mentioned generic substances in 
1993–94 and 2003–04. Five of these 
drugs were among the top 10 in both 
time periods. However, aspirin use 
increased, from 1.1 percent of total drug 
mentions in 1993–94 to 1.8 percent of 
total drug mentions in 2003–04, while 
use of amoxicillin decreased. Estrogen 
was no longer among the most 
frequently mentioned drugs in 2003–04. 
Additional Information 
Ambulatory care visit and drug data 
from NAMCS and NHAMCS are 
available in a variety of formats 
including CD-ROM and downloadable 
data files accessed through the 
Ambulatory Health Care Data homepage 
on the Internet at http://www.cdc.gov/ 
nchs/namcs.htm. For additional 
information concerning NAMCS and 
NHAMCS data, contact the Ambulatory 
Care Statistics Branch at 
(301) 458–4600. 
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Table 1. Annual number and percent distribution of ambulatory care visits by medication therapy, according to setting type: United States, 
2003–04 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Medication therapy settings offices offices offices departments departments 
Number of visits in thousands 
All visits . . . . . . . . . . . . . . . . . . .  1,110,285  533,239 179,569 195,632 89,786 112,060 
Was medication therapy 
provided or prescribed? 
Yes . . . . . . . . . . . . . . . . . . . . . .  736,930 373,836 73,339 143,070 59,491 87,193 
No  . . . . . . . . . . . . . . . . . . . . . .  373,355 159,402 106,230 52,562 30,294 24,866 
Number of medications 
provided or prescribed 
None . . . . . . . . . . . . . . . . . . . . .  373,355 159,402 106,230 52,562 30,294 24,866 
1  . . . . . . . . . . . . . . . . . . . . . . .  285,641 148,522 37,957 47,900 21,269 29,993 
2  . . . . . . . . . . . . . . . . . . . . . . .  175,985 88,066 18,544 29,694 14,366 25,315 
3  . . . . . . . . . . . . . . . . . . . . . . .  97,771  48,388  7,720  18,737  8,056  14,870  
4  . . . . . . . . . . . . . . . . . . . . . . .  56,746  28,673  3,436  11,732  5,123  7,781  
5  . . . . . . . . . . . . . . . . . . . . . . .  35,947  17,869  2,088  9,034  3,244  3,712  
6  . . . . . . . . . . . . . . . . . . . . . . .  25,832  14,062  1,228  6,408  2,167  1,968  
7  . . . . . . . . . . . . . . . . . . . . . . .  16,836  8,386  740  5,019  1,438  1,252  
8  . . . . . . . . . . . . . . . . . . . . . . .  42,173  19,871  1,626  14,545  3,829  2,302  
Medication therapy Standard error in thousands 
All visits . . . . . . . . . . . . . . . . . . .  30,603  21,112  8,898  12,670  6,534  3,920  
Was medication therapy 
provided or prescribed? 
Yes . . . . . . . . . . . . . . . . . . . . . .  20,834  15,165  4,407  9,604  4,659  3,263  
No  . . . . . . . . . . . . . . . . . . . . . .  13,873  8,988  5,993  4,928  2,304  946  
Number of medications 
provided or prescribed 
None . . . . . . . . . . . . . . . . . . . . .  13,873  8,988  5,993  4,928  2,304  946  
1  . . . . . . . . . . . . . . . . . . . . . . .  8,678  6,832  2,392  3,959  1,601  1,155  
2  . . . . . . . . . . . . . . . . . . . . . . .  5,415  4,318  1,364  2,194  1,183  990  
3  . . . . . . . . . . . . . . . . . . . . . . .  3,599  2,822  780  1,556  706  637  
4  . . . . . . . . . . . . . . . . . . . . . . .  2,467  1,902  541  1,082  452  389  
5  . . . . . . . . . . . . . . . . . . . . . . .  1,863  1,387  364  924  337  211  
6  . . . . . . . . . . . . . . . . . . . . . . .  1,629  1,336  229  753  272  149  
7  . . . . . . . . . . . . . . . . . . . . . . .  1,284  914  147  655  178  118  
8  . . . . . . . . . . . . . . . . . . . . . . .  3,449  2,327  313  1,996  684  313  
Percent distribution 
All visits . . . . . . . . . . . . . . . . . . .  100.0 100.0 100.0 100.0 100.0 100.0 
Was medication therapy 
provided or prescribed? 
Yes . . . . . . . . . . . . . . . . . . . . . .  66.4  70.1  40.8  73.1  66.3  77.8  
No  . . . . . . . . . . . . . . . . . . . . . .  33.6  29.9  59.2  26.9  33.7  22.2  
Number of medications 
provided or prescribed 
None . . . . . . . . . . . . . . . . . . . . .  33.6  29.9  59.2  26.9  33.7  22.2  
1  . . . . . . . . . . . . . . . . . . . . . . .  25.7  27.9  21.1  24.5  23.7  26.8  
2  . . . . . . . . . . . . . . . . . . . . . . .  15.9  16.5  10.3  15.2  16.0  22.6  
3  . . . . . . . . . . . . . . . . . . . . . . .  8.8  9.1  4.3  9.6  9.0  13.3  
4  . . . . . . . . . . . . . . . . . . . . . . .  5.1  5.4  1.9  6.0  5.7  6.9  
5  . . . . . . . . . . . . . . . . . . . . . . .  3.2  3.4  1.2  4.6  3.6  3.3  
6  . . . . . . . . . . . . . . . . . . . . . . .  2.3  2.6  0.7  3.3  2.4  1.8  
7  . . . . . . . . . . . . . . . . . . . . . . .  1.5  1.6  0.4  2.6  1.6  1.1  
8  . . . . . . . . . . . . . . . . . . . . . . .  3.8  3.7  0.9  7.4  4.3  2.1  
Standard error of percent 
All visits . . . . . . . . . . . . . . . . . . .  . . .  . . .  . . .  . . .  . . .  . . .  
See footnotes at end of table. 
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Table 1. Annual number and percent distribution of ambulatory care visits by medication therapy, according to setting type: United States, 
2003–04—Con. 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Medication therapy settings offices offices offices departments departments 
Was medication therapy 
provided or prescribed? Standard error of percent 
Yes  . . . . . . . . . . . . . . . . . . . . . .  0.7  1.1  1.5  1.7  1.3  0.6  
No  . . . . . . . . . . . . . . . . . . . . . .  0.7  1.1  1.5  1.7  1.3  0.6  
Number of medications 
provided or prescribed 
None  . . . . . . . . . . . . . . . . . . . . .  0.7  1.1  1.5  1.7  1.3  0.6  
1  . . . . . . . . . . . . . . . . . . . . . . .  0.4  0.7  0.8  1.2  0.7  0.5  
2  . . . . . . . . . . . . . . . . . . . . . . .  0.3  0.4  0.6  0.6  0.6  0.3  
3  . . . . . . . . . . . . . . . . . . . . . . .  0.2  0.4  0.4  0.5  0.4  0.2  
4  . . . . . . . . . . . . . . . . . . . . . . .  0.2  0.3  0.3  0.4  0.3  0.2  
5  . . . . . . . . . . . . . . . . . . . . . . .  0.1  0.2  0.2  0.4  0.3  0.1  
6  . . . . . . . . . . . . . . . . . . . . . . .  0.1  0.2  0.1  0.3  0.2  0.1  
7  . . . . . . . . . . . . . . . . . . . . . . .  0.1  0.2  0.1  0.3  0.2  0.1  
8  . . . . . . . . . . . . . . . . . . . . . . .  0.3  0.4  0.2  0.9  0.6  0.3  
. . . Category not applicable.

NOTES: Numbers may not add to totals due to rounding. Figures are annual averages.
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Table 2. Annual number and percent distribution of drug mentions at ambulatory care visits by setting type, according to selected patient 
and provider characteristics: United States, 2003–04 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Characteristic settings offices offices offices departments departments 
Number of mentions in thousands 
All  drug  mentions  . . . . . . . . . . . . . . . . . .  1,947,870 975,895 147,946 445,540 164,578 213,909 
Patient age 
Under 15 years . . . . . . . . . . . . . . . . . . .  241,084 146,852 5,387 26,317 27,698 34,830 
Under 1 year . . . . . . . . . . . . . . . . . . .  43,626  32,093  *262  *838  5,020  5,412  
1–4 years . . . . . . . . . . . . . . . . . . . . .  79,213  49,127  1,663  *5,530  9,107  13,786  
5–14 years. . . . . . . . . . . . . . . . . . . . .  118,244  65,632  3,461  19,949  13,571  15,632  
15–24 years . . . . . . . . . . . . . . . . . . . . .  120,800 53,850 4,983 20,580 12,903 28,484 
25–44 years . . . . . . . . . . . . . . . . . . . . .  364,590 167,024 22,377 73,861 37,119 64,209 
45–64 years . . . . . . . . . . . . . . . . . . . . .  597,672 298,796 48,258 150,498 52,387 47,732 
65–74 years . . . . . . . . . . . . . . . . . . . . .  279,779 135,358 27,952 81,495 18,997 15,977 
75 years and over . . . . . . . . . . . . . . . . .  343,945 174,016 38,989 92,789 15,474 22,677 
Patient sex 
Female  . . . . . . . . . . . . . . . . . . . . . . . .  1,148,849 599,064 81,696 248,689 100,537 118,863 
Male  . . . . . . . . . . . . . . . . . . . . . . . . . .  799,021 376,832 66,250 196,852 64,041 95,046 
Patient race1 
White  . . . . . . . . . . . . . . . . . . . . . . . . .  1,614,647 817,980 128,031 387,891 119,991 160,755 
Black  or  African  American  . . . . . . . . . . . . .  249,623 113,179 13,167 40,478 36,729 46,071 
Asian  . . . . . . . . . . . . . . . . . . . . . . . . .  64,623  35,103  5,291  *14,601  5,299  4,328  
Native Hawaiian or other Pacific Islander . . . 6,838 4,223 *591 * 493 850 
American Indian or Alaska Native . . . . . . . .  6,738  *2,314  *579  *1,510  902  1,434  
More  than  one  race  reported  . . . . . . . . . . .  5,400  3,097  *  *  *1,164  472  
Patient ethnicity1 
Hispanic or Latino. . . . . . . . . . . . . . . . . .  202,480 107,021 13,798 30,719 24,252 26,689 
Not Hispanic or Latino . . . . . . . . . . . . . . .  1,745,390 868,874 134,148 414,821 140,326 187,220 
Primary expected source of payment 
Private insurance . . . . . . . . . . . . . . . . . .  920,614 515,199 66,738 204,730 57,421 76,526 
Medicare  . . . . . . . . . . . . . . . . . . . . . . .  570,885 269,288 56,782 169,850 34,124 40,841 
Medicaid  . . . . . . . . . . . . . . . . . . . . . . .  243,226 109,263 7,629 32,284 48,582 45,469 
Uninsured. . . . . . . . . . . . . . . . . . . . . . .  105,732 45,141 10,798 20,776 10,175 18,841 
Other  . . . . . . . . . . . . . . . . . . . . . . . . .  107,413 37,004 6,000 17,900 14,277 32,233 
Geographic region of provider 
Northeast . . . . . . . . . . . . . . . . . . . . . . .  393,710 192,292 25,339 86,304 49,587 40,187 
Midwest  . . . . . . . . . . . . . . . . . . . . . . . .  438,332 227,202 25,579 94,034 45,141 46,376 
South  . . . . . . . . . . . . . . . . . . . . . . . . .  698,911 344,673 53,410 166,881 50,642 83,305 
West  . . . . . . . . . . . . . . . . . . . . . . . . . .  416,917 211,728 43,618 98,322 19,208 44,042 
MSA2 status of provider 
MSA  . . . . . . . . . . . . . . . . . . . . . . . . . .  1,664,627 807,305 132,188 413,631 131,330 180,173 
Not  MSA  . . . . . . . . . . . . . . . . . . . . . . .  283,242 168,590 15,758 31,909 *33,249 33,736 
Percent distribution 
All  visits  . . . . . . . . . . . . . . . . . . . . . . . .  100.0 50.1 7.6 22.9 8.4 11.0 
Patient age 
Under 15 years . . . . . . . . . . . . . . . . . . .  100.0 60.9 2.2 10.9 11.5 14.4 
Under 1 year . . . . . . . . . . . . . . . . . . .  100.0 73.6 0.6 1.9 11.5 12.4 
1–4 years . . . . . . . . . . . . . . . . . . . . .  100.0 62.0 2.1 7.0 11.5 17.4 
5–14 years. . . . . . . . . . . . . . . . . . . . .  100.0 55.5 2.9 16.9 11.5 13.2 
15–24 years . . . . . . . . . . . . . . . . . . . . .  100.0 44.6 4.1 17.0 10.7 23.6 
25–44 years . . . . . . . . . . . . . . . . . . . . .  100.0 45.8 6.1 20.3 10.2 17.6 
45–64 years . . . . . . . . . . . . . . . . . . . . .  100.0 50.0 8.1 25.2 8.8 8.0 
65–74 years . . . . . . . . . . . . . . . . . . . . .  100.0 48.4 10.0 29.1 6.8 5.7 
75 years and over . . . . . . . . . . . . . . . . .  100.0 50.6 11.3 27.0 4.5 6.6 
See footnotes at end of table. 
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Table 2. Annual number and percent distribution of drug mentions at ambulatory care visits by setting type, according to selected patient 
and provider characteristics: United States, 2003–04—Con. 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Characteristic settings offices offices offices departments departments 
Patient sex Percent distribution 
Female  . . . . . . . . . . . . . . . . . . . . . . . .  100.0 52.1 7.1 21.6 8.8 10.3 
Male  . . . . . . . . . . . . . . . . . . . . . . . . . .  100.0 47.2 8.3 24.6 8.0 11.9 
Patient race1 
White  . . . . . . . . . . . . . . . . . . . . . . . . .  100.0 50.7 7.9 24.0 7.4 10.0 
Black  or  African  American  . . . . . . . . . . . . .  100.0 45.3 5.3 16.2 14.7 18.5 
Asian  . . . . . . . . . . . . . . . . . . . . . . . . .  100.0 54.3 8.2 22.6 8.2 6.7 
Native Hawaiian or other Pacific Islander . . . 100.0 61.8 8.6 * 7.2 12.4 
American Indian or Alaska Native . . . . . . . .  100.0 34.3 8.6 22.4 13.4 21.3 
More  than  one  race  reported  . . . . . . . . . . .  100.0 57.3 * * 21.6 8.7 
Patient ethnicity1 
Hispanic or Latino. . . . . . . . . . . . . . . . . .  100.0 52.9 6.8 15.2 12.0 13.2 
Not Hispanic or Latino . . . . . . . . . . . . . . .  100.0 49.8 7.7 23.8 8.0 10.7 
Primary expected source of payment 
Private insurance . . . . . . . . . . . . . . . . . .  100.0 56.0 7.2 22.2 6.2 8.3 
Medicare  . . . . . . . . . . . . . . . . . . . . . . .  100.0 47.2 9.9 29.8 6.0 7.2 
Medicaid  . . . . . . . . . . . . . . . . . . . . . . .  100.0 44.9 3.1 13.3 20.0 18.7 
Uninsured. . . . . . . . . . . . . . . . . . . . . . .  100.0 42.7 10.2 19.7 9.6 17.8 
Other  . . . . . . . . . . . . . . . . . . . . . . . . .  100.0 34.5 5.6 16.7 13.3 30.0 
Geographic region of provider 
Northeast . . . . . . . . . . . . . . . . . . . . . . .  100.0 48.8 6.4 21.9 12.6 10.2 
Midwest  . . . . . . . . . . . . . . . . . . . . . . . .  100.0 51.8 5.8 21.5 10.3 10.6 
South  . . . . . . . . . . . . . . . . . . . . . . . . .  100.0 49.3 7.6 23.9 7.2 11.9 
West  . . . . . . . . . . . . . . . . . . . . . . . . . .  100.0 50.8 10.5 23.6 4.6 10.6 
MSA2 status of provider 
MSA  . . . . . . . . . . . . . . . . . . . . . . . . . .  100.0 48.5 7.9 24.8 7.9 10.8 
Not  MSA  . . . . . . . . . . . . . . . . . . . . . . .  100.0 59.5 5.6 11.3 11.7 11.9 
* Figure does not meet standard of reliability or precision.

1Persons of Hispanic or Latino origin may be of any race or combination of races. Similarly, the category ‘‘Not Hispanic or Latino’’ refers to all persons who are not of Hispanic or Latino origin,

regardless of race. Starting with data year 1999, race-specific estimates have been tabulated according to the 1997 standards for federal data on race and Hispanic or Latino origin and are not strictly

comparable with estimates for earlier years. See Appendix I for details.

2MSA is Metropolitan Statistical Area.

NOTES: Numbers may not add to totals due to rounding. Figures are annual averages. 
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Table 3. Annual rate of drug mentions at ambulatory care visits, by setting type and selected patient and provider characteristics: 
United States, 2003–04 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Characteristic settings offices offices offices departments departments 
Number of mentions per 100 visits1 
All  visits  . . . . . . . . . . . . . . . . . . . . . . . .  175.4 183.0 82.4 227.7 183.3 190.9 
Patient age 
Under 15 years . . . . . . . . . . . . . . . . . . .  126.4 123.5 42.7 174.3 136.4 146.1 
Under 1 year . . . . . . . . . . . . . . . . . . .  127.4 127.5 *29.5 *110.6 142.1 138.8 
1–4 years . . . . . . . . . . . . . . . . . . . . .  130.9 127.1 49.1 *172.3 142.6 155.3 
5–14 years. . . . . . . . . . . . . . . . . . . . .  123.2 119.2 41.6 179.1 130.6 141.3 
15–24 years . . . . . . . . . . . . . . . . . . . . .  120.7 109.9 51.7 160.0 120.2 159.7 
25–44 years . . . . . . . . . . . . . . . . . . . . .  143.3 133.2 67.8 182.3 161.8 197.5 
45–64 years . . . . . . . . . . . . . . . . . . . . .  196.2 218.8 82.4 229.5 230.6 224.6 
65–74 years . . . . . . . . . . . . . . . . . . . . .  226.1 274.0 91.8 271.1 266.9 239.0 
75 years and over . . . . . . . . . . . . . . . . .  251.5 322.2 110.5 294.4 259.6 227.9 
Patient sex 
Female  . . . . . . . . . . . . . . . . . . . . . . . .  176.3 181.8 83.1 229.1 183.5 196.6 
Male  . . . . . . . . . . . . . . . . . . . . . . . . . .  174.2 185.1 81.5 226.1 182.9 184.1 
Patient race2 
White  . . . . . . . . . . . . . . . . . . . . . . . . .  174.4 183.9 80.6 224.9 182.1 191.8 
Black  or  African  American  . . . . . . . . . . . . .  183.9 185.3 90.2 262.1 185.9 185.6 
Asian  . . . . . . . . . . . . . . . . . . . . . . . . .  169.9 163.5 106.5 *218.3 188.9 206.8 
Native Hawaiian or other Pacific Islander . . . 189.3 196.0 *136.4 * 167.7 199.4 
American Indian or Alaska Native . . . . . . . .  193.2 *172.3 *121.1 *289.2 196.0 209.3 
More  than  one  race  reported  . . . . . . . . . . .  146.2 126.6 * * *202.4 197.4 
Patient ethnicity2 
Hispanic or Latino. . . . . . . . . . . . . . . . . .  160.0 160.6 86.2 206.4 166.2 185.0 
Not Hispanic or Latino . . . . . . . . . . . . . . .  177.4 186.2 82.0 229.5 186.6 191.8 
Primary expected source of payment 
Private insurance . . . . . . . . . . . . . . . . . .  157.7 160.3 75.7 205.4 168.4 189.4 
Medicare  . . . . . . . . . . . . . . . . . . . . . . .  240.6 290.3 101.3 294.4 261.4 230.5 
Medicaid  . . . . . . . . . . . . . . . . . . . . . . .  172.0 163.6 75.3 230.8 186.4 186.0 
Uninsured. . . . . . . . . . . . . . . . . . . . . . .  151.1 168.1 58.5 155.2 151.5 180.4 
Other  . . . . . . . . . . . . . . . . . . . . . . . . .  138.0 149.6 72.3 162.9 142.3 162.1 
Geographic region of provider 
Northeast . . . . . . . . . . . . . . . . . . . . . . .  173.4 188.5 71.3 205.1 203.2 174.4 
Midwest  . . . . . . . . . . . . . . . . . . . . . . . .  181.5 196.7 66.9 260.9 175.9 178.3 
South  . . . . . . . . . . . . . . . . . . . . . . . . .  167.3 172.6 78.1 213.1 178.3 193.5 
West  . . . . . . . . . . . . . . . . . . . . . . . . . .  186.3 182.6 116.6 250.8 169.7 220.7 
MSA3 status of provider 
MSA  . . . . . . . . . . . . . . . . . . . . . . . . . .  172.9 177.7 82.7 229.4 176.6 192.0 
Not  MSA  . . . . . . . . . . . . . . . . . . . . . . .  191.7 213.3 79.5 208.6 *215.6 185.1 
Standard error of rate 
All  visits  . . . . . . . . . . . . . . . . . . . . . . . .  4.6  7.0  4.8  12.2  8.3  4.1  
Patient age 
Under 15 years . . . . . . . . . . . . . . . . . . .  3.2  4.1  4.9  14.1  5.3  3.6  
Under 1 year . . . . . . . . . . . . . . . . . . .  5.7  7.5  9.0  41.8  8.4  4.4  
1–4 years . . . . . . . . . . . . . . . . . . . . .  4.1  5.7  7.1  20.6  6.2  4.8  
5–14 years. . . . . . . . . . . . . . . . . . . . .  3.5  4.1  5.1  13.1  6.8  3.5  
15–24 years . . . . . . . . . . . . . . . . . . . . .  2.8  4.7  4.3  7.5  5.2  3.0  
25–44 years . . . . . . . . . . . . . . . . . . . . .  3.6  5.3  5.4  9.0  7.3  3.7  
45–64 years . . . . . . . . . . . . . . . . . . . . .  6.3  10.8  5.3  12.8  12.5  6.0  
65–74 years . . . . . . . . . . . . . . . . . . . . .  8.3  13.6  6.7  19.6  18.9  9.8  
75 years and over . . . . . . . . . . . . . . . . .  10.2  17.8  8.8  21.7  23.8  10.4  
See footnotes at end of table. 
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Table 3. Annual rate of drug mentions at ambulatory care visits, by setting type and selected patient and provider characteristics: 
United States, 2003–04—Con. 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Characteristic settings offices offices offices departments departments 
Patient sex Standard error of rate 
Female  . . . . . . . . . . . . . . . . . . . . . . . .  5.0  7.6  5.3  13.1  8.9  4.7  
Male  . . . . . . . . . . . . . . . . . . . . . . . . . .  4.7  7.5  4.8  12.9  8.2  3.6  
Patient race2 
White  . . . . . . . . . . . . . . . . . . . . . . . . .  4.8  7.5  4.8  12.1  10.1  4.2  
Black  or  African  American  . . . . . . . . . . . . .  7.2  11.9  8.3  19.6  7.4  5.0  
Asian  . . . . . . . . . . . . . . . . . . . . . . . . .  14.1  20.3  18.6  36.1  26.0  10.5  
Native Hawaiian or other Pacific Islander . . . 14.8 25.9 30.1 * 19.7 11.7 
American Indian or Alaska Native . . . . . . . .  18.1  28.9  26.4  69.9  22.6  20.7  
More  than  one  race  reported  . . . . . . . . . . .  12.8  15.4  *  *  18.2  20.0  
Patient ethnicity2 
Hispanic or Latino. . . . . . . . . . . . . . . . . .  7.4  15.6  11.5  24.6  9.2  5.0  
Not Hispanic or Latino . . . . . . . . . . . . . . .  4.9  7.0  4.7  12.1  9.2  4.3  
Primary expected source of payment 
Private insurance . . . . . . . . . . . . . . . . . .  4.6  6.2  4.7  11.1  9.7  3.7  
Medicare  . . . . . . . . . . . . . . . . . . . . . . .  9.0  16.0  7.5  19.8  16.4  9.5  
Medicaid  . . . . . . . . . . . . . . . . . . . . . . .  5.7  9.5  7.9  21.6  9.6  4.7  
Uninsured. . . . . . . . . . . . . . . . . . . . . . .  5.1  8.9  12.3  11.7  8.7  2.8  
Other  . . . . . . . . . . . . . . . . . . . . . . . . .  5.9  11.1  10.6  18.3  6.7  5.2  
Geographic region of provider 
Northeast . . . . . . . . . . . . . . . . . . . . . . .  12.9  17.1  8.7  27.7  22.4  8.7  
Midwest  . . . . . . . . . . . . . . . . . . . . . . . .  8.5  13.5  6.2  27.4  13.2  5.8  
South  . . . . . . . . . . . . . . . . . . . . . . . . .  7.1  11.2  7.8  17.3  9.2  7.3  
West  . . . . . . . . . . . . . . . . . . . . . . . . . .  9.1  14.4  13.8  30.0  16.0  10.4  
MSA3 status of provider 
MSA  . . . . . . . . . . . . . . . . . . . . . . . . . .  5.0  7.7  5.2  12.7  6.8  4.2  
Not  MSA  . . . . . . . . . . . . . . . . . . . . . . .  11.8  14.3  7.6  35.2  32.1  12.2  
* Figure does not meet standard of reliability or precision.

1Number of drug mentions divided by total number of visits multiplied by 100.

2Persons of Hispanic or Latino origin may be of any race or combination of races. Similarly, the category ‘‘Not Hispanic or Latino’’ refers to all persons who are not of Hispanic or Latino origin,

regardless of race. Starting with data year 1999, race-specific estimates have been tabulated according to the 1997 standards for federal data on race and Hispanic or Latino origin and are not strictly

comparable with estimates for earlier years. See Appendix I for details.

3MSA is Metropolitan Statistical Area.

NOTE: Figures are annual averages. 
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Table 4. Number and percent distribution of drug mentions at ambulatory care visits with corresponding standard errors, by selected drug 
characteristics according to setting type: United States, 2003–04 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Characteristic settings offices offices offices departments departments 
All  drug  mentions  . . . . . . . . . . . . .  1,947,870 975,895 147,946 445,540 164,578 213,909 
Prescription status Number of mentions in thousands 
Prescription . . . . . . . . . . . . . . . . .  1,611,601  818,055 122,314 379,071 132,797 159,363 
Non-prescription1 . . . . . . . . . . . . .  191,145 91,188 14,268 35,288 19,523 30,877 
Undetermined status . . . . . . . . . . .  145,124 66,652 11,364 31,181 12,258 23,669 
Federal control status2 
Schedule II . . . . . . . . . . . . . . . . .  43,513  13,569  1,909  9,230  3,921  14,884  
Schedule III . . . . . . . . . . . . . . . . .  44,801  18,633  4,799  4,750  3,077  13,543  
Schedule IV . . . . . . . . . . . . . . . .  60,154  24,764  3,557  19,482  5,049  7,301  
Schedule V . . . . . . . . . . . . . . . . .  7,058  4,700  *  1,018  566  671  
No  control . . . . . . . . . . . . . . . . . .  1,724,512 885,181 131,296 388,161 147,682 172,193 
Undetermined . . . . . . . . . . . . . . .  67,832  29,049  6,282  22,900  4,283  5,317  
Standard error in thousands 
All  drug  mentions  . . . . . . . . . . . . .  72,398  50,268  10,949  36,163  15,408  9,218  
Prescription status 
Prescription . . . . . . . . . . . . . . . . .  59,393  42,136  9,218  30,251  12,535  6,904  
Non-prescription1 . . . . . . . . . . . . .  8,957  6,267  1,465  3,825  1,986  1,496  
Undetermined status . . . . . . . . . . .  7,549  4,875  1,081  4,039  1,124  1,153  
Federal control status2 
Schedule II . . . . . . . . . . . . . . . . .  2,031  1,173  352  1,066  602  690  
Schedule III . . . . . . . . . . . . . . . . .  2,562  1,849  681  874  393  700  
Schedule IV . . . . . . . . . . . . . . . .  3,035  1,999  652  1,854  743  325  
Schedule V . . . . . . . . . . . . . . . . .  654  609  .  .  .  235  86  56  
No  control . . . . . . . . . . . . . . . . . .  65,532  46,018  9,657  32,427  13,877  7,672  
Undetermined . . . . . . . . . . . . . . .  4,507  2,406  740  3,467  417  393  
Percent distribution 
All  drug  mentions  . . . . . . . . . . . . .  100.0 100.0 100.0 100.0 100.0 100.0 
Prescription status 
Prescription . . . . . . . . . . . . . . . . .  82.7  83.8  82.7  85.1  80.7  74.5  
Non-prescription1 . . . . . . . . . . . . .  9.8  9.3  9.6  7.9  11.9  14.4  
Undetermined status . . . . . . . . . . .  7.5  6.8  7.7  7.0  7.4  11.1  
Federal control status2 
Schedule II . . . . . . . . . . . . . . . . .  2.2  1.4  1.3  2.1  2.4  7.0  
Schedule III . . . . . . . . . . . . . . . . .  2.3  1.9  3.2  1.1  1.9  6.3  
Schedule IV . . . . . . . . . . . . . . . .  3.1  2.5  2.4  4.4  3.1  3.4  
Schedule V . . . . . . . . . . . . . . . . .  0.4  0.5  *  0.2  0.3  0.3  
No  control . . . . . . . . . . . . . . . . . .  88.5  90.7  88.7  87.1  89.7  80.5  
Undetermined . . . . . . . . . . . . . . .  3.5  3.0  4.2  5.1  2.6  2.5  
Standard error of percent 
All  drug  mentions  . . . . . . . . . . . . .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  
Prescription status 
Prescription . . . . . . . . . . . . . . . . .  0.4  0.6  0.9  0.8  0.6  0.5  
Non-prescription1 . . . . . . . . . . . . .  0.2  0.4  0.7  0.4  0.4  0.3  
Undetermined status . . . . . . . . . . .  0.2  0.3  0.5  0.7  0.3  0.3  
See footnotes at end of table. 
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Table 4. Number and percent distribution of drug mentions at ambulatory care visits with corresponding standard errors, by selected drug 
characteristics according to setting type: United States, 2003–04—Con. 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Characteristic settings offices offices offices departments departments 
Federal control status2 Standard error of percent 
Schedule II . . . . . . . . . . . . . . . . .  0.1  0.1  0.2  0.2  0.3  0.2 

Schedule III . . . . . . . . . . . . . . . . .  0.1  0.2  0.4  0.2  0.2  0.2 

Schedule IV . . . . . . . . . . . . . . . .  0.1  0.1  0.4  0.3  0.3  0.1 

Schedule V . . . . . . . . . . . . . . . . .  0.0  0.1  . . .  0.1  0.0  0.0 

No control . . . . . . . . . . . . . . . . . .  0.3  0.3  0.7  0.9  0.7  0.4 

Undetermined . . . . . . . . . . . . . . .  0.2  0.2  0.4  0.7  0.1  0.1 

* Figure does not meet standard of reliability or precision. 
. . . Not applicable. 
0.0 Quantity more than zero, but less than 0.05. 
1Nonprescription preparations include over-the-counter (OTC) products. Drug characteristics are defined in Appendix II. 
2See Appendix II for an explanation of federal control status. 
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Table 5. Annual rate of broad therapeutic classes of drug mentions at ambulatory care visits, by setting type: United States, 2003–04 
Primary Surgical Medical Hospital Hospital 
Combined care specialty specialty outpatient emergency 
Broad therapeutic class1 settings offices offices offices departments departments 
Number of occurrences per 100 visits 
Anesthetics and adjuncts . . . . . . . . . . . . . . . . . . . . . . .  1.9  1.0  2.6  1.8  2.8  4.5  
Antidotes  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.2  *0.0  *0.2  0.4  *0.2  0.4  
Antimicrobial agents . . . . . . . . . . . . . . . . . . . . . . . . . .  16.0  18.8  7.8  8.9  18.0  27.2  
Hematologic agents . . . . . . . . . . . . . . . . . . . . . . . . . .  3.9  3.5  1.1  7.8  4.7  2.9  
Cardiovascular-renal drugs. . . . . . . . . . . . . . . . . . . . . .  25.2  28.9  9.2  37.4  23.0  13.8  
Central nervous system . . . . . . . . . . . . . . . . . . . . . . . .  17.6  15.4  3.0  36.9  18.5  17.5  
Contrast media and radiopharmaceuticals . . . . . . . . . . . .  0.1  *0.1  *0.0  *0.3  *0.1  0.1  
Gastrointestinal agents . . . . . . . . . . . . . . . . . . . . . . . .  9.1  9.9  2.9  11.4  9.6  11.0  
Metabolics  and  nutrients  . . . . . . . . . . . . . . . . . . . . . . .  15.2  18.1  4.2  21.8  15.0  8.1  
Hormones and hormonal mechanisms. . . . . . . . . . . . . . .  15.2  18.8  6.1  17.4  15.5  8.7  
Immunologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6.3  8.5  *0.4  6.8  8.2  3.0  
Skin/mucous membranes. . . . . . . . . . . . . . . . . . . . . . .  7.1  5.9  3.8  14.8  6.6  5.4  
Neurologic  drugs  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5.5  4.2  1.8  11.6  6.7  5.9  
Oncolytics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1.2  0.4  0.7  4.1  1.9  0.1  
Ophthlamics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4.4  1.5  17.8  1.6  3.3  2.8  
Otics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2.7  2.0  0.8  1.5  2.6  11.5  
Relief  of  pain  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25.7  22.8  14.0  21.6  27.2  64.7  
Antiparasitics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.8  0.9  0.2  0.6  1.2  0.8  
Respiratory tract . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20.7  24.1  6.2  22.1  21.6  24.3  
Unclassified and miscellaneous . . . . . . . . . . . . . . . . . . .  3.7  3.4  2.3  5.1  3.1  5.3  
Homeopathic products . . . . . . . . . . . . . . . . . . . . . . . .  0.6  0.7  0.4  0.8  0.4  0.1  
Standard error of rate 
Anesthetics and adjuncts . . . . . . . . . . . . . . . . . . . . . . .  0.1  0.2  0.5  0.3  0.4  0.2  
Antidotes  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.0  0.0  0.1  0.1  0.1  0.0  
Antimicrobial agents . . . . . . . . . . . . . . . . . . . . . . . . . .  0.5  0.8  0.5  1.3  1.1  0.6  
Hematologic agents . . . . . . . . . . . . . . . . . . . . . . . . . .  0.2  0.3  0.2  0.9  0.5  0.2  
Cardiovascular-renal drugs. . . . . . . . . . . . . . . . . . . . . .  1.2  1.9  1.2  3.7  1.9  0.8  
Central nervous system . . . . . . . . . . . . . . . . . . . . . . . .  0.6  0.9  0.5  2.3  1.5  0.6  
Contrast media and radiopharmaceuticals . . . . . . . . . . . .  0.0  0.0  0.0  0.1  0.0  0.0  
Gastrointestinal agents . . . . . . . . . . . . . . . . . . . . . . . .  0.4  0.5  0.4  1.2  0.7  0.4  
Metabolics  and  nutrients  . . . . . . . . . . . . . . . . . . . . . . .  0.8  1.2  0.5  2.4  1.3  0.5  
Hormones and hormonal mechanisms. . . . . . . . . . . . . . .  0.6  0.9  0.6  1.9  1.0  0.4  
Immunologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.4  0.7  0.2  1.4  0.7  0.1  
Skin and mucous membranes . . . . . . . . . . . . . . . . . . . .  0.2  0.3  0.4  1.0  0.4  0.2  
Neurologic  drugs  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.2  0.3  0.4  0.8  0.5  0.2  
Oncolytics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.2  0.1  0.1  0.9  0.3  0.0  
Ophthlamics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.3  0.1  1.9  0.4  0.4  0.1  
Otics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.1  0.2  0.1  0.2  0.2  0.3  
Relief  of  pain  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.7  1.2  1.4  1.8  1.6  1.0  
Antiparasitics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.1  0.1  0.0  0.1  0.1  0.0  
Respiratory tract . . . . . . . . . . . . . . . . . . . . . . . . . . . .  0.8  1.1  0.6  3.2  1.3  0.5  
Unclassified and miscellaneous . . . . . . . . . . . . . . . . . . .  0.3  0.4  0.3  0.6  0.3  0.4  
Homeopathic products . . . . . . . . . . . . . . . . . . . . . . . .  0.1  0.1  0.1  0.2  0.1  0.0  
* Figure does not meet standard of reliability or precision.

0.0 Quantity is greater than zero but less than 0.05.

1Based on the standard drug classification used in the National Drug Code Directory, 1995 edition (NDC) (12). In the NDC, therapeutic classes are assigned to drugs using 21 broad categories (2-digit

level), and into specific categories (4-digit level) within each broad group. In NAMCS and NHAMCS, up to three therapeutic classes can be coded for each drug. Drugs are counted in each class in

which they occur.

NOTE: Figures are annual averages. 
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Table 6. Annual rate of the top 10 broad therapeutic classes of drugs provided, prescribed, or continued at ambulatory care visits, with 
corresponding standard errors, by setting type: United States, 2003–04 
Setting type and Number of occurrences Standard error 
broad therapeutic class1 per 100 visits of rate 
Primary care offices 
Cardiovascular-renal . . . . . . . . . . . . . . . . . . . . . . .  28.9 1.9

Respiratory tract . . . . . . . . . . . . . . . . . . . . . . . . . .  24.1  1.1 

Relief of pain . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22.8  1.2 

Hormones and hormonal mechanisms . . . . . . . . . . . .  18.8 0.9

Antimicrobial agents . . . . . . . . . . . . . . . . . . . . . . .  18.8  0.8 

Metabolics and nutrients . . . . . . . . . . . . . . . . . . . . .  18.1  1.2 

Central nervous system . . . . . . . . . . . . . . . . . . . . .  15.4 0.9

Gastrointestinal agents . . . . . . . . . . . . . . . . . . . . . .  9.9  0.5 

Immunologics . . . . . . . . . . . . . . . . . . . . . . . . . . .  8.5 0.7

Skin and mucous membranes . . . . . . . . . . . . . . . . .  5.9 0.3

Surgical specialty offices 
Ophthalmics  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17.8  1.9 

Relief of pain . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14.0  1.4 

Cardiovascular-renal . . . . . . . . . . . . . . . . . . . . . . .  9.2 1.2

Antimicrobial agents . . . . . . . . . . . . . . . . . . . . . . .  7.8 0.5

Respiratory tract . . . . . . . . . . . . . . . . . . . . . . . . . .  6.2  0.6 

Hormones and hormonal mechanisms . . . . . . . . . . . .  6.1  0.6 

Metabolics and nutrients . . . . . . . . . . . . . . . . . . . . .  4.2  0.5 

Skin and mucous membranes . . . . . . . . . . . . . . . . .  3.8 0.4

Central nervous system . . . . . . . . . . . . . . . . . . . . .  3.0 0.5

Gastrointestinal agents . . . . . . . . . . . . . . . . . . . . . .  2.9  0.4 

Medical specialty offices 
Cardiovascular-renal . . . . . . . . . . . . . . . . . . . . . . .  37.4 3.7

Central nervous system . . . . . . . . . . . . . . . . . . . . .  36.9 2.3

Respiratory tract . . . . . . . . . . . . . . . . . . . . . . . . . .  22.1  3.2 

Metabolics and nutrients . . . . . . . . . . . . . . . . . . . . .  21.8  2.4 

Relief of pain . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21.6  1.8 

Hormones and hormonal mechanisms . . . . . . . . . . . .  17.4 1.9

Skin and mucous membranes . . . . . . . . . . . . . . . . .  14.8  1.0 

Neurologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  11.6  0.8 

Gastrointestinal agents . . . . . . . . . . . . . . . . . . . . . .  11.4  1.2 

Antimicrobial agents . . . . . . . . . . . . . . . . . . . . . . .  8.9 1.3

Hospital outpatient departments 
Relief of pain . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27.2  1.6 

Cardiovascular-renal . . . . . . . . . . . . . . . . . . . . . . .  23.0 1.9

Respiratory tract . . . . . . . . . . . . . . . . . . . . . . . . . .  21.6  1.3 

Central nervous system . . . . . . . . . . . . . . . . . . . . .  18.5 1.5

Antimicrobial agents . . . . . . . . . . . . . . . . . . . . . . .  18.0 1.1

Hormones and hormonal mechanisms . . . . . . . . . . . .  15.5  1.0 

Metabolics and nutrients . . . . . . . . . . . . . . . . . . . . .  15.0  1.3 

Gastrointestinal agents . . . . . . . . . . . . . . . . . . . . . .  9.6  0.7 

Immunologics . . . . . . . . . . . . . . . . . . . . . . . . . . .  8.2  0.7 

Neurologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6.7  0.5 

Hospital emergency departments 
Relief of pain . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64.7  1.0 

Antimicrobial agents . . . . . . . . . . . . . . . . . . . . . . .  27.2 0.6

Respiratory tract . . . . . . . . . . . . . . . . . . . . . . . . . .  24.3  0.5 

Central nervous system . . . . . . . . . . . . . . . . . . . . .  17.5 0.6

Cardiovascular-renal . . . . . . . . . . . . . . . . . . . . . . .  13.8  0.8 

Otics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  11.5  0.3 

Gastrointestinal agents . . . . . . . . . . . . . . . . . . . . . .  11.0  0.4 

Hormones and hormonal mechanisms . . . . . . . . . . . .  8.7  0.4 

Metabolics and nutrients . . . . . . . . . . . . . . . . . . . . .  8.1  0.5 

Neurologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5.9  0.2 

1Based on the standard drug classification used in the National Drug Code Directory, 1995 edition (NDC) (12). In the NDC, therapeutic classes are assigned to drugs using 21 broad categories (2-digit 
level), and into specific categories (4-digit level) within each broad group. In NAMCS and NHAMCS, up to three therapeutic classes can be coded for each drug. Drugs are counted in each class in 
which they occur. 
NOTE: Figures are annual averages. 
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Table 7. Annual number and rate of therapeutic classes of drugs provided, prescribed, or continued at ambulatory care visits, with percent 
distribution by setting type and corresponding standard errors: United States, 2003–2004 
Number of 
Number of occurrences Primary Surgical Medical Hospital Hospital 
occurrences per 1,000 care specialty specialty outpatient emergency 
Therapeutic class1 in thousands2 drug mentions3 Total offices offices offices departments departments 
Percent distribution 
All occurrences . . . . . . . . . . . . . . . . . . . . . .  2,240,800 1,150.4 100.0 49.7 7.4 22.5 8.4 12.0 
Anesthetics and adjuncts. . . . . . . . . . . . . . . .  20,929  10.7  100.0 24.5 22.4 17.1 11.9 24.0 
Anesthetics, local (injectable). . . . . . . . . . . .  13,034  6.7  100.0 23.5 30.5 16.9 9.3 19.8 
Anesthetics, general . . . . . . . . . . . . . . . . .  *1,162  *0.6  100.0 * * * *47.6 *16.9 
Adjuncts to anesthesia and analeptics . . . . . .  3,488  1.8  100.0 * * *18.5 8.6 54.6 
Medicinal gases . . . . . . . . . . . . . . . . . . . .  1,643  0.8  100.0 * * * *8.6 40.4 
Anesthetics, topical . . . . . . . . . . . . . . . . . .  1,696  0.9  100.0 * * 42.4 10.3 15.3 
Anesthetics, rectal . . . . . . . . . . . . . . . . . .  522  0.3  100.0 * * * *12.5 13.0 
Antidotes  . . . . . . . . . . . . . . . . . . . . . . . . .  1,820  0.9  100.0 * * 42.1 *10.6 23.3 
Antidotes, specific. . . . . . . . . . . . . . . . . . .  681  0.3  100.0 * * * *20.8 37.5 
Antidotes, general. . . . . . . . . . . . . . . . . . .  590  0.3  100.0 * * * * 27.6 
Antitoxins or antivenins . . . . . . . . . . . . . . .  551  0.3  100.0 * * *35.4 * * 
Antimicrobial agents. . . . . . . . . . . . . . . . . . .  178,179 91.5 100.0 56.2 7.9 9.8 9.1 17.1 
Penicillins . . . . . . . . . . . . . . . . . . . . . . . .  44,824  23.0  100.0 65.4 3.8 4.1 10.6 16.1 
Cephalosporins . . . . . . . . . . . . . . . . . . . .  30,104  15.5  100.0 52.1 7.9 4.1 7.9 28.0 
Lincosamides and macrolides . . . . . . . . . . .  31,362  16.1  100.0 63.3 3.7 8.6 8.7 15.7 
Tetracyclines . . . . . . . . . . . . . . . . . . . . . .  8,564  4.4  100.0 49.2 6.3 30.7 6.4 7.4 
Aminoglycosides . . . . . . . . . . . . . . . . . . .  2,024  1.0  100.0 43.7 * * 10.6 18.1 
Sulfonamides and trimethoprim . . . . . . . . . .  9,566  4.9  100.0 54.8 5.0 13.2 9.6 17.5 
Urinary tract antiseptics . . . . . . . . . . . . . . .  4,495  2.3  100.0 50.6 19.1 11.5 9.3 9.5 
Miscellaneous antibacterial agents . . . . . . . .  11,495  5.9  100.0 36.2 31.0 11.1 6.8 14.9 
Antimycobacterial and anti-leprosy agents . . . .  347  0.2  100.0 * * * *18.3 * 
Quinolones and derivatives . . . . . . . . . . . . .  19,787  10.2  100.0 54.3 12.1 5.7 6.8 21.1 
Antifungals . . . . . . . . . . . . . . . . . . . . . . .  4,304  2.2  100.0 62.4 * 20.7 12.0 2.6 
Antiviral agents . . . . . . . . . . . . . . . . . . . .  10,440  5.4  100.0 44.4 * *33.7 12.7 5.6 
Hematologic agents . . . . . . . . . . . . . . . . . . .  43,571  22.4  100.0 43.4 4.5 35.0 9.7 7.4 
Deficiency anemias . . . . . . . . . . . . . . . . . .  17,971  9.2  100.0 51.2 2.0 33.9 10.0 2.8 
Anticoagulants and thrombolytics . . . . . . . . .  25,022  12.8  100.0 38.2 6.4 35.5 9.6 10.2 
Blood components and substitutes . . . . . . . .  *174  *0.1  100.0 * * * * *25.2 
Hemostatics  . . . . . . . . . . . . . . . . . . . . . .  358  0.2  100.0 * * * *8.6 31.7 
Cardiovascular-renal drugs . . . . . . . . . . . . . .  279,710 143.6 100.0 55.0 5.9 26.2 7.4 5.5 
Cardiac glycosides . . . . . . . . . . . . . . . . . .  7,907  4.1  100.0 45.6 5.8 36.4 6.8 5.4 
Antiarrhythmic agents . . . . . . . . . . . . . . . .  4,624  2.4  100.0 37.2 * 40.1 5.4 13.2 
Antianginal agents . . . . . . . . . . . . . . . . . .  12,596  6.5  100.0 35.7 3.4 33.7 5.3 21.8 
Vascular disorders, cerebral and peripheral . . . 7,841 4.0 100.0 59.0 18.3 *16.6 5.5 0.6 
Agents used to treat shock and hypotension . . 1,211 0.6 100.0 * * * *9.1 44.4 
Antihypertensive agents . . . . . . . . . . . . . . .  69,625  35.7  100.0 61.5 5.6 24.1 6.0 2.7 
Diuretics  . . . . . . . . . . . . . . . . . . . . . . . .  50,605  26.0  100.0 54.1 4.4 27.0 8.4 6.0 
Coronary vasodilators . . . . . . . . . . . . . . . .  693  0.4  100.0 * * * *8.0 37.9 
Relaxants and stimulants, urinary tract . . . . . .  4,746  2.4  100.0 57.6 22.9 10.7 6.2 2.6 
Calcium channel blockers . . . . . . . . . . . . . .  37,156  19.1  100.0 57.8 4.7 25.5 7.6 4.4 
Carbonic anhydrase inhibitors . . . . . . . . . . .  480  0.2  100.0 * * * *10.0 * 
Beta blockers . . . . . . . . . . . . . . . . . . . . .  46,478  23.9  100.0 53.5 4.9 29.1 8.4 4.1 
Alpha agonists and alpha blockers . . . . . . . .  24,320  12.5  100.0 45.4 10.4 30.3 7.0 6.9 
ACE4 inhibitors  . . . . . . . . . . . . . . . . . . . .  49,721  25.5  100.0 61.8 4.5 22.5 8.1 3.1 
Central nervous system . . . . . . . . . . . . . . . .  195,747 100.5 100.0 41.9 2.7 36.9 8.5 10.0 
Sedatives and hypnotics. . . . . . . . . . . . . . .  34,523  17.7  100.0 37.1 3.6 19.6 9.2 30.5 
Antianxiety agents . . . . . . . . . . . . . . . . . .  32,505  16.7  100.0 41.1 4.3 34.6 6.5 13.5 
Antipsychotics and antimanics . . . . . . . . . . .  17,382  8.9  100.0 20.2 * 59.7 12.3 7.2 
Antidepressants . . . . . . . . . . . . . . . . . . . .  89,218  45.8  100.0 47.2 2.7 38.8 8.6 2.7 
Anorexiants and CNS5 stimulants  . . . . . . . . .  13,195  6.8  100.0 54.5 * 37.2 6.8 1.2 
CNS, miscellaneous . . . . . . . . . . . . . . . . .  3,180  1.6  100.0 34.3 * 52.0 7.1 2.1 
Alzheimer-type dementia . . . . . . . . . . . . . .  3,286  1.7  100.0 56.7 * 34.7 3.5 3.6 
Antiemetics  . . . . . . . . . . . . . . . . . . . . . . .  2,629  1.3  100.0 * * 53.2 *8.8 23.9 
Contrast media and radiopharmaceuticals . . . . .  1,195  0.6  100.0 * * 46.3 *8.4 12.7 
Diagnostics, radiopaque and nonradioactive . . 870 0.4 100.0 * * 44.4 *10.6 17.2 
Gastrointestinal agents . . . . . . . . . . . . . . . . .  101,157 51.9 100.0 52.1 5.1 22.0 8.5 12.2 
Disorders, acid and peptic. . . . . . . . . . . . . .  68,140  35.0  100.0 54.2 4.6 22.6 8.5 10.0 
Antidiarrheals . . . . . . . . . . . . . . . . . . . . .  5,585  2.9  100.0 53.3 * 19.9 7.5 16.3 
Laxatives . . . . . . . . . . . . . . . . . . . . . . . .  13,494  6.9  100.0 47.6 *8.6 22.4 11.0 10.4 
See footnotes at end of table. 
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Table 7. Annual number and rate of therapeutic classes of drugs provided, prescribed, or continued at ambulatory care visits, with percent 
distribution by setting type and corresponding standard errors: United States, 2003–2004—Con. 
Number of 
Number of occurrences Primary Surgical Medical Hospital Hospital 
occurrences per 1,000 care specialty specialty outpatient emergency 
Therapeutic class1 in thousands2 drug mentions3 Total offices offices offices departments departments 
Percent distribution 
Gastrointestinal agents—Con. 
Miscellaneous gastrointestinals . . . . . . . . . .  7,561  3.9  100.0 49.2 *5.1 24.4 4.3 17.0 
Antispasmodics and anticholinergics . . . . . . .  3,341  1.7  100.0 44.6 8.0 * 7.4 23.8 
Antacids. . . . . . . . . . . . . . . . . . . . . . . . .  3,662  1.9  100.0 40.2 * 15.8 9.6 32.4 
Metabolics  and  nutrients  . . . . . . . . . . . . . . . .  169,099 86.8 100.0 57.1 4.4 25.2 8.0 5.3 
Hyperlipidemia . . . . . . . . . . . . . . . . . . . . .  69,358  35.6  100.0 61.7 4.2 25.1 6.9 2.0 
Vitamins  and  minerals  . . . . . . . . . . . . . . . .  49,789  25.6  100.0 59.4 5.2 22.2 10.1 3.0 
Nutrition,  enteral  and  parenteral  . . . . . . . . . .  3,561  1.8  100.0 49.3 * 27.0 9.5 13.6 
Replenishers, regulators of electrolytes and 
water balance . . . . . . . . . . . . . . . . . . . .  28,914  14.8  100.0 45.6 4.8 23.6 7.2 18.8 
Calcium  metabolism  . . . . . . . . . . . . . . . . .  13,929  7.2  100.0 61.6 3.1 28.2 6.0 1.1 
Hematopoietic growth factors. . . . . . . . . . . .  2,968  1.5  100.0 * * 75.9 *9.6 *2.3 
Hormones and hormonal mechanisms . . . . . . .  168,893 86.7 100.0 59.3 6.5 20.2 8.2 5.8 
Adrenal corticosteroids. . . . . . . . . . . . . . . .  40,653  20.9  100.0 43.6 11.2 23.5 8.0 13.7 
Androgens and anabolic steroids . . . . . . . . .  4,940  2.5  100.0 60.1 17.4 17.2 4.4 *0.9 
Estrogens and progestins . . . . . . . . . . . . . .  22,849  11.7  100.0 70.4 4.6 15.4 7.7 1.8 
Anterior pituitary and hypothalmic function. . . .  324  0.2  100.0 * * * *25.0 * 
Blood glucose regulators . . . . . . . . . . . . . .  59,559  30.6  100.0 60.7 4.2 21.3 9.3 4.4 
Thyroid and antithyroid. . . . . . . . . . . . . . . .  26,168  13.4  100.0 60.9 5.0 24.8 6.5 2.8 
Antidiuretics  . . . . . . . . . . . . . . . . . . . . . .  183  0.1  100.0 * * * * * 
Relaxants and stimulants, uterine . . . . . . . . .  *391  *0.2  100.0 * * * *18.4 *11.1 
Contraceptives. . . . . . . . . . . . . . . . . . . . .  14,472  7.4  100.0 83.8 * 4.8 8.1 1.7 
Growth hormone secretion disorders . . . . . . .  967  0.5  100.0 * 42.2 * *12.3 * 
Immunologics . . . . . . . . . . . . . . . . . . . . . . .  70,073  36.0  100.0 64.7 *1.0 18.9 10.6 4.9 
Vaccines and antisera . . . . . . . . . . . . . . . .  55,085  28.3  100.0 79.3 * *2.7 11.8 6.0 
Immunomodulators . . . . . . . . . . . . . . . . . .  3,753  1.9  100.0 * * 64.1 16.6 3.0 
Allergenic extracts . . . . . . . . . . . . . . . . . .  10,785  5.5  100.0 *9.2 *4.8 84.2 *1.7 * 
Immune  serums  . . . . . . . . . . . . . . . . . . . .  881  0.5  100.0 * * * *9.6 21.4 
Skin and mucous membranes. . . . . . . . . . . . .  79,135  40.6  100.0 39.6 8.7 36.6 7.5 7.6 
Antiseptics and disinfectants . . . . . . . . . . . .  4,966  2.5  100.0 22.8 *8.5 52.1 5.5 11.1 
Dermatologics, miscellaneous . . . . . . . . . . .  23,400  12.0  100.0 47.0 3.4 36.9 7.6 5.0 
Keratolytics  . . . . . . . . . . . . . . . . . . . . . . .  541  0.3  100.0 * * 58.7 *9.7 * 
Topical  steroids  . . . . . . . . . . . . . . . . . . . .  20,998  10.8  100.0 36.3 14.2 35.7 6.8 7.0 
Burn and sunburn, sunscreen and suntan 
products . . . . . . . . . . . . . . . . . . . . . . . .  420  0.2  100.0 * * 72.4 * * 
Acne products . . . . . . . . . . . . . . . . . . . . .  5,672  2.9  100.0 16.9 * 76.5 4.6 * 
Topical  anti-infectives. . . . . . . . . . . . . . . . .  12,398  6.4  100.0 50.0 5.3 27.5 9.6 7.7 
Anorectal products . . . . . . . . . . . . . . . . . .  *136  *0.1  100.0 * * * * * 
Dermatitis  and  antipruritics  . . . . . . . . . . . . .  1,563  0.8  100.0 * * 38.6 8.5 5.6 
Topical analgesics . . . . . . . . . . . . . . . . . .  9,910  5.1  100.0 38.1 18.7 16.9 8.4 18.0 
Neurologic  drugs. . . . . . . . . . . . . . . . . . . . .  60,978  31.3  100.0 36.9 5.3 37.1 9.8 10.9 
Extrapyramidal movement disorders . . . . . . .  4,137  2.1  100.0 * * 59.0 9.5 4.9 
Myasthenia gravis. . . . . . . . . . . . . . . . . . .  *86  *0.0  100.0 * * * * * 
Skeletal muscle hyperactivity . . . . . . . . . . . .  23,781  12.2  100.0 50.4 7.9 15.7 8.2 17.8 
Anticonvulsants . . . . . . . . . . . . . . . . . . . .  37,664  19.3  100.0 30.3 4.1 46.7 10.6 8.4 
Oncolytics . . . . . . . . . . . . . . . . . . . . . . . . .  13,119  6.7  100.0 15.4 9.3 61.1 12.9 1.2 
Antineoplastics, miscellaneous . . . . . . . . . . .  4,658  2.4  100.0 * *5.0 70.1 11.4 1.3 
Hormonal and biological response modulators . 3,822 2.0 100.0 * 22.5 47.1 8.9 1.6 
Antimetabolites  . . . . . . . . . . . . . . . . . . . .  2,434  1.2  100.0 * * 56.8 13.8 * 
Antibiotics, alkaloids, and enzymes . . . . . . . .  432  0.2  100.0 * * 68.3 *21.6 * 
DNA  damaging  drugs  . . . . . . . . . . . . . . . .  1,588  0.8  100.0 * * 69.0 *24.3 * 
Ophthalmics. . . . . . . . . . . . . . . . . . . . . . . .  49,201  25.3  100.0 16.3 65.1 6.3 6.1 6.3 
Glaucoma. . . . . . . . . . . . . . . . . . . . . . . .  12,516  6.4  100.0 7.9 80.8 4.6 5.8 0.9 
Cycloplegics  and  mydriatics  . . . . . . . . . . . .  2,884  1.5  100.0 * 61.5 * 12.8 20.9 
Ocular anti-infective and anti-inflammatory . . . 21,341 11.0 100.0 22.4 57.7 *6.7 6.2 7.0 
Miscellaneous ophthalmics . . . . . . . . . . . . .  9,784  5.0  100.0 12.3 69.7 * 4.5 8.0 
Decongestants and antiallergy agents . . . . . .  2,039  1.0  100.0 40.4 32.1 * *3.4 2.8 
Otics  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30,101  15.5  100.0 34.9 4.9 9.7 7.7 42.8 
Otic, topical (miscellaneous) . . . . . . . . . . . .  4,923  2.5  100.0 57.8 15.5 * 10.2 14.3 
Vertigo, motion sickness, and vomiting . . . . . .  25,179  12.9  100.0 30.4 *2.8 11.2 7.3 48.4 
Relief  of  pain  . . . . . . . . . . . . . . . . . . . . . . .  285,792 146.7 100.0 42.5 8.8 14.8 8.5 25.4 
General analgesics . . . . . . . . . . . . . . . . . .  5,813  3.0  100.0 48.5 11.6 23.9 5.8 10.3 
Narcotic analgesics . . . . . . . . . . . . . . . . . .  78,516  40.3  100.0 30.5 9.8 13.0 7.7 39.0 
See footnotes at end of table. 
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Table 7. Annual number and rate of therapeutic classes of drugs provided, prescribed, or continued at ambulatory care visits, with percent 
distribution by setting type and corresponding standard errors: United States, 2003–2004—Con. 
Number of 
Number of occurrences Primary Surgical Medical Hospital Hospital 
occurrences per 1,000 care specialty specialty outpatient emergency 
Therapeutic class1 in thousands2 drug mentions3 Total offices offices offices departments departments 
Percent distribution 
Relief of pain—Con. 
Nonnarcotic analgesics . . . . . . . . . . . . . . .  76,480  39.3  100.0 46.3 4.0 19.5 10.0 20.2 
Antimigraine and other headaches . . . . . . . .  6,741  3.5  100.0 70.0 * 16.1 7.2 4.5 
Antiarthritics  . . . . . . . . . . . . . . . . . . . . . .  66,733  34.3  100.0 50.3 11.7 24.0 7.5 6.5 
Antigout . . . . . . . . . . . . . . . . . . . . . . . . .  5,110  2.6  100.0 51.2 * 36.7 4.9 3.5 
NSAID6 . . . . . . . . . . . . . . . . . . . . . . . . .  111,974  57.5  100.0 46.7 11.0 11.0 8.6 22.7 
Antipyretics  . . . . . . . . . . . . . . . . . . . . . . .  69,924  35.9  100.0 46.0 3.7 19.4 10.1 20.8 
Antiparasitics  . . . . . . . . . . . . . . . . . . . . . . .  8,382  4.3  100.0 58.3 4.2 15.0 12.4 10.0 
Antiprotozoals . . . . . . . . . . . . . . . . . . . . .  6,213  3.2  100.0 60.6 3.3 11.8 12.5 11.8 
Scabicides and pediculicides . . . . . . . . . . . .  *309  *0.2  100.0 * * * * * 
Antimalarials  . . . . . . . . . . . . . . . . . . . . . .  2,179  1.1  100.0 52.5 * 28.4 10.0 3.1 
Respiratory tract . . . . . . . . . . . . . . . . . . . . .  229,591 117.9 100.0 56.0 4.9 18.8 8.4 11.8 
Antiasthmatics and bronchodilators . . . . . . . .  79,790  41.0  100.0 51.8 3.1 26.1 7.9 11.1 
Nasal decongestants . . . . . . . . . . . . . . . . .  17,284  8.9  100.0 66.7 9.0 5.5 11.0 7.9 
Antitussives, expectorants. and mucolytics . . . 30,186 15.5 100.0 68.7 4.4 7.8 10.5 8.6 
Antihistamines  . . . . . . . . . . . . . . . . . . . . .  79,432  40.8  100.0 53.2 4.2 17.0 7.7 17.8 
Cold  remedies  . . . . . . . . . . . . . . . . . . . . .  8,201  4.2  100.0 74.1 *3.7 * 8.2 7.1 
Corticosteroid - inhalation and nasal . . . . . . .  30,950  15.9  100.0 58.8 10.0 20.5 8.8 1.9 
Unclassified and miscellaneous. . . . . . . . . . . .  40,782  20.9  100.0 44.1 9.9 24.5 6.8 14.7 
Unclassified . . . . . . . . . . . . . . . . . . . . . .  34,543  17.7  100.0 48.1 10.2 26.4 6.6 8.8 
Pharmaceutical aids . . . . . . . . . . . . . . . . .  4,386  2.3  100.0 * *2.6 * 7.1 63.0 
Surgical  aids  . . . . . . . . . . . . . . . . . . . . . .  1,832  0.9  100.0 * * * *4.7 68.5 
Homeopathic products . . . . . . . . . . . . . . . . .  6,521  3.3  100.0 58.4 10.3 25.3 4.9 1.1 
Standard Standard 
error in error 
Therapeutic class1 thousands of rate Standard error of percent 
All  drug  mentions  . . . . . . . . . . . . . . . . . . . .  72,398  2.6  .  .  .  1.6  0.5  1.5  0.8  0.6  
Anesthetics and adjuncts. . . . . . . . . . . . . . . .  1,482  0.8  .  .  .  3.8  3.6  2.9  1.9  1.8  
Anesthetics, local (Injectable). . . . . . . . . . . .  1,240  0.6  .  .  .  5.8  5.1  3.5  1.5  2.0  
Anesthetics, general . . . . . . . . . . . . . . . . .  360  0.2  .  .  .  .  .  .  .  .  .  .  .  .  15.1  5.4  
Adjuncts to anesthesia and analeptics . . . . . .  326  0.2  .  .  .  .  .  .  .  .  .  5.6  2.1  4.9  
Medicinal gases . . . . . . . . . . . . . . . . . . . .  267  0.1  .  .  .  .  .  .  .  .  .  .  .  .  3.7  7.1  
Anesthetics, topical . . . . . . . . . . . . . . . . . .  345  0.2  .  .  .  .  .  .  .  .  .  12.0  2.8  3.6  
Anesthetics, rectal . . . . . . . . . . . . . . . . . .  118  0.1  .  .  .  .  .  .  .  .  .  .  .  .  3.9  3.4  
Antidotes  . . . . . . . . . . . . . . . . . . . . . . . . .  256  0.1  .  .  .  .  .  .  .  .  .  7.7  4.2  3.3  
Antidotes, specific. . . . . . . . . . . . . . . . . . .  118  0.1  .  .  .  .  .  .  .  .  .  .  .  .  9.1  6.8  
Antidotes, general. . . . . . . . . . . . . . . . . . .  167  0.1  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  7.7  
Antitoxins or antivenins . . . . . . . . . . . . . . .  161  0.1  .  .  .  .  .  .  .  .  .  12.2  .  .  .  .  .  .  
Antimicrobial agents. . . . . . . . . . . . . . . . . . .  6,998  3.4  .  .  .  1.8  0.6  1.4  0.9  0.9  
Penicillins . . . . . . . . . . . . . . . . . . . . . . . .  2,459  1.2  .  .  .  2.0  0.6  0.9  1.3  1.1  
Cephalosporins . . . . . . . . . . . . . . . . . . . .  1,633  0.8  .  .  .  2.4  1.2  0.7  1.0  1.7  
Lincosamides and macrolides . . . . . . . . . . .  1,759  0.9  .  .  .  2.2  0.6  1.2  1.1  1.1  
Tetracyclines . . . . . . . . . . . . . . . . . . . . . .  759  0.4  .  .  .  3.8  1.3  3.1  1.1  0.8  
Aminoglycosides . . . . . . . . . . . . . . . . . . .  231  0.1  .  .  .  6.6  .  .  .  .  .  .  2.4  2.3  
Sulfonamides and trimethoprim . . . . . . . . . .  808  0.4  .  .  .  4.4  0.9  3.8  1.2  1.9  
Urinary tract antiseptics . . . . . . . . . . . . . . .  343  0.2  .  .  .  3.8  2.4  2.7  1.3  1.0  
Miscellaneous antibacterial agents . . . . . . . .  793  0.4  .  .  .  3.8  3.6  1.6  0.8  1.3  
Antimycobacterial and anti-leprosy agents . . . .  103  0.1  .  .  .  .  .  .  .  .  .  .  .  .  7.5  .  .  .  
Quinolones and derivatives . . . . . . . . . . . . .  911  0.5  .  .  .  2.3  1.2  0.9  0.8  1.2  
Antifungals . . . . . . . . . . . . . . . . . . . . . . .  461  0.2  .  .  .  5.1  .  .  .  5.0  2.9  0.5  
Antiviral agents . . . . . . . . . . . . . . . . . . . .  1,902  1.0  .  .  .  8.4  .  .  .  11.3  3.6  1.2  
Hematologic agents . . . . . . . . . . . . . . . . . . .  2,771  1.0  .  .  .  3.0  0.9  3.2  1.3  0.7  
Deficiency anemias . . . . . . . . . . . . . . . . . .  1,706  0.7  .  .  .  4.6  0.5  5.1  1.4  0.4  
Anticoagulants and thrombolytics . . . . . . . . .  1,599  0.6  .  .  .  3.2  1.3  2.9  1.6  0.9  
Blood components and substitutes . . . . . . . .  107  0.1  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  16.0  
Hemostatics  . . . . . . . . . . . . . . . . . . . . . .  89  0.0  .  .  .  .  .  .  .  .  .  .  .  .  3.5  8.3  
Cardiovascular-renal drugs . . . . . . . . . . . . . .  15,315  4.0  .  .  .  2.3  0.8  2.2  0.9  0.5  
Cardiac glycosides . . . . . . . . . . . . . . . . . .  611  0.3  .  .  .  4.1  1.7  3.9  1.3  0.7  
Antiarrythmic agents . . . . . . . . . . . . . . . . .  433  0.2  .  .  .  4.8  .  .  .  4.3  1.5  1.6  
Antianginal agents . . . . . . . . . . . . . . . . . .  981  0.4  .  .  .  3.1  1.0  3.2  0.9  2.0  
See footnotes at end of table. 
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Table 7. Annual number and rate of therapeutic classes of drugs provided, prescribed, or continued at ambulatory care visits, with percent 
distribution by setting type and corresponding standard errors: United States, 2003–2004—Con. 
Number of 
Number of occurrences Primary Surgical Medical Hospital Hospital 
occurrences per 1,000 care specialty specialty outpatient emergency 
Therapeutic class1 in thousands2 drug mentions3 Total offices offices offices departments departments 
Standard Standard 
error in error 
thousands of rate Standard error of percent 
Cardiovascular-renal drugs—Con. 
Vascular disorders, cerebral and peripheral . . . 801 0.4 . . . 4.9 2.6 5.7 1.0 0.2 
Agents used to treat shock and hypotension . . 230 0.1 . . . . . . . . . . . . 2.7 8.6 
Antihypertensive agents . . . . . . . . . . . . . . .  4,320  1.4  .  .  .  2.9  0.9  2.6  0.8  0.3  
Diuretics  . . . . . . . . . . . . . . . . . . . . . . . .  3,025  1.0  .  .  .  2.9  0.8  2.9  1.0  0.6  
Coronary vasodilators . . . . . . . . . . . . . . . .  102  0.1  .  .  .  .  .  .  .  .  .  .  .  .  3.0  6.1  
Relaxants and stimulants, urinary tract . . . . . .  455  0.2  .  .  .  4.2  2.7  2.5  1.2  0.5  
Calcium channel blockers . . . . . . . . . . . . . .  2,381  0.8  .  .  .  2.6  1.0  2.4  1.0  0.5  
Carbonic anhydrase inhibitors . . . . . . . . . . .  100  0.1  .  .  .  .  .  .  .  .  .  .  .  .  4.2  .  .  .  
Beta blockers . . . . . . . . . . . . . . . . . . . . .  2,762  0.9  .  .  .  2.5  0.8  2.4  1.2  0.4  
Alpha agonists and alpha blockers . . . . . . . .  1,428  0.5  .  .  .  2.7  1.2  2.5  1.0  0.6  
ACE4 inhibitors  . . . . . . . . . . . . . . . . . . . .  3,007  0.9  .  .  .  2.5  0.8  2.2  1.0  0.4  
Central nervous system . . . . . . . . . . . . . . . .  8,530  2.7  .  .  .  1.9  0.4  2.0  1.0  0.6  
Sedatives and hypnotics. . . . . . . . . . . . . . .  1,852  0.7  .  .  .  2.3  0.9  1.8  1.4  1.7  
Antianxiety agents . . . . . . . . . . . . . . . . . .  1,714  0.6  .  .  .  2.6  0.8  2.7  1.0  0.8  
Antipsychotics and antimanics . . . . . . . . . . .  1,460  0.7  .  .  .  2.8  .  .  .  3.5  1.8  0.8  
Antidepressants . . . . . . . . . . . . . . . . . . . .  4,106  1.4  .  .  .  2.1  0.4  2.2  1.1  0.3  
Anorexiants and CNS5 stimulants  . . . . . . . . .  1,418  0.7  .  .  .  4.9  .  .  .  4.6  1.3  0.3  
CNS, miscellaneous . . . . . . . . . . . . . . . . .  383  0.2  .  .  .  5.7  .  .  .  5.9  1.4  0.5  
Alzheimer-type dementia . . . . . . . . . . . . . .  545  0.3  .  .  .  7.4  .  .  .  6.4  1.0  0.9  
Antiemetics  . . . . . . . . . . . . . . . . . . . . . . .  561  0.3  .  .  .  .  .  .  .  .  .  10.1  3.0  5.8  
Contrast media and radiopharmaceuticals . . . . .  219  0.1  .  .  .  .  .  .  .  .  .  10.3  3.5  3.4  
Diagnostics, radiopaque and nonradioactive . . 147 0.1 . . . . . . . . . 10.6 4.6 4.6 
Gastrointestinal agents . . . . . . . . . . . . . . . . .  5,429  1.5  .  .  .  2.2  0.7  2.3  1.0  0.7  
Disorders, acid and peptic. . . . . . . . . . . . . .  3,759  1.0  .  .  .  2.3  0.6  2.4  1.0  0.7  
Antidiarrheals . . . . . . . . . . . . . . . . . . . . .  547  0.2  .  .  .  4.0  .  .  .  3.3  1.4  1.9  
Laxatives . . . . . . . . . . . . . . . . . . . . . . . .  1,292  0.6  .  .  .  4.9  3.0  5.1  1.7  1.0  
Miscellaneous gastrointestinals . . . . . . . . . .  705  0.3  .  .  .  3.5  1.7  3.3  0.7  1.8  
Antispasmodics and anticholinergics . . . . . . .  306  0.1  .  .  .  4.8  2.0  .  .  .  1.4  2.4  
Antacids. . . . . . . . . . . . . . . . . . . . . . . . .  344  0.2  .  .  .  4.8  .  .  .  3.4  1.7  3.0  
Metabolics  and  nutrients  . . . . . . . . . . . . . . . .  9,842  2.7  .  .  .  2.5  0.6  2.4  1.0  0.4  
Hyperlipidemia . . . . . . . . . . . . . . . . . . . . .  4,440  1.3  .  .  .  2.6  0.7  2.3  1.0  0.3  
Vitamins  and  minerals  . . . . . . . . . . . . . . . .  3,383  1.2  .  .  .  2.8  0.8  2.5  1.3  0.4  
Nutrition,  enteral  and  parenteral  . . . . . . . . . .  411  0.2  .  .  .  5.7  .  .  .  5.7  1.9  1.8  
Replenishers, regulators of electrolytes and 
water balance . . . . . . . . . . . . . . . . . . . .  1,931  0.7  .  .  .  3.1  0.9  3.4  1.1  1.5  
Calcium  metabolism  . . . . . . . . . . . . . . . . .  1,281  0.5  .  .  .  4.6  0.7  4.5  1.3  0.2  
Hematopoietic growth factors. . . . . . . . . . . .  814  0.4  .  .  .  .  .  .  .  .  .  7.5  3.4  0.8  
Hormones and hormonal mechanisms . . . . . . .  8,421  2.4  .  .  .  2.2  0.7  2.2  0.9  0.4  
Adrenal corticosteroids. . . . . . . . . . . . . . . .  2,122  0.9  .  .  .  2.6  1.4  3.1  0.8  1.0  
Androgens and anabolic steroids . . . . . . . . .  946  0.5  .  .  .  7.7  3.8  5.0  1.1  0.3  
Estrogens and progestins . . . . . . . . . . . . . .  1,730  0.7  .  .  .  2.7  1.0  2.3  1.2  0.3  
Anterior pituitary and hypothalmic function. . . .  97  0.0  .  .  .  .  .  .  .  .  .  .  .  .  8.4  .  .  .  
Blood glucose regulators . . . . . . . . . . . . . .  4,134  1.6  .  .  .  3.1  0.8  3.1  1.2  0.4  
Thyroid and antithyroid. . . . . . . . . . . . . . . .  1,861  0.7  .  .  .  3.4  1.1  3.6  1.0  0.4  
Antidiuretics  . . . . . . . . . . . . . . . . . . . . . .  47  0.0  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  
Relaxants and stimulants, uterine . . . . . . . . .  182  0.1  .  .  .  .  .  .  .  .  .  .  .  .  11.1  6.0  
Contraceptives. . . . . . . . . . . . . . . . . . . . .  1,271  0.6  .  .  .  2.0  .  .  .  1.2  1.3  0.3  
Growth hormone secretion disorders . . . . . . .  164  0.1  .  .  .  .  .  .  7.7  .  .  .  5.2  .  .  .  
Immunologics . . . . . . . . . . . . . . . . . . . . . . .  4,622  2.3  .  .  .  3.7  0.4  3.7  1.4  0.4  
Vaccines and antisera . . . . . . . . . . . . . . . .  3,608  1.9  .  .  .  2.1  .  .  .  0.9  1.7  0.5  
Immunomodulators . . . . . . . . . . . . . . . . . .  751  0.4  .  .  .  .  .  .  .  .  .  8.2  4.3  0.8  
Allergenic extracts . . . . . . . . . . . . . . . . . .  2,971  1.5  .  .  .  5.1  2.9  6.4  0.6  .  .  .  
Immune  serums  . . . . . . . . . . . . . . . . . . . .  202  0.1  .  .  .  .  .  .  .  .  .  .  .  .  3.2  5.6  
Skin and mucous membrane . . . . . . . . . . . . .  3,265  1.5  .  .  .  1.9  1.1  2.0  0.7  0.5  
Antiseptics and disinfectants . . . . . . . . . . . .  494  0.2  .  .  .  3.6  3.0  4.7  1.6  1.5  
Dermatologics, miscellaneous . . . . . . . . . . .  1,287  0.6  .  .  .  2.4  0.9  2.3  0.8  0.4  
Keratolytics  . . . . . . . . . . . . . . . . . . . . . . .  91  0.0  .  .  .  .  .  .  .  .  .  8.5  3.2  .  .  .  
Topical  steroids  . . . . . . . . . . . . . . . . . . . .  1,306  0.6  .  .  .  3.0  2.7  2.9  0.9  0.6  
See footnotes at end of table. 
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Table 7. Annual number and rate of therapeutic classes of drugs provided, prescribed, or continued at ambulatory care visits, with percent 
distribution by setting type and corresponding standard errors: United States, 2003–2004—Con. 
Number of 
Number of occurrences Primary Surgical Medical Hospital Hospital 
occurrences per 1,000 care specialty specialty outpatient emergency 
Therapeutic class1 in thousands2 drug mentions3 Total offices offices offices departments departments 
Standard Standard 
error in error 
thousands of rate Standard error of percent 
Skin and mucous membrane—Con. 
Burn and sunburn, sunscreen and suntan 
products . . . . . . . . . . . . . . . . . . . . . . . .  108  0.1  .  .  .  .  .  .  .  .  .  9.6  .  .  .  .  .  .  
Acne products . . . . . . . . . . . . . . . . . . . . .  540  0.3  .  .  .  4.0  .  .  .  4.2  0.9  .  .  .  
Topical  anti-infectives. . . . . . . . . . . . . . . . .  740  0.3  .  .  .  3.1  0.9  2.7  1.0  0.8  
Anorectal products . . . . . . . . . . . . . . . . . .  49  0.0  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  
Dermatitis  and  antipruritics  . . . . . . . . . . . . .  215  0.1  .  .  .  .  .  .  .  .  .  5.4  2.2  1.4  
Topical analgesics . . . . . . . . . . . . . . . . . .  1,059  0.5  .  .  .  6.4  3.4  3.7  1.5  2.1  
Neurologic  drugs. . . . . . . . . . . . . . . . . . . . .  2,793  1.0  .  .  .  2.0  1.1  2.2  1.0  0.7  
Extrapyramidal movement disorders . . . . . . .  452  0.2  .  .  .  .  .  .  .  .  .  4.9  1.7  0.9  
Myasthenia gravis. . . . . . . . . . . . . . . . . . .  32  0.0  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  
Skeletal muscle hyperactivity . . . . . . . . . . . .  1,245  0.6  .  .  .  2.8  2.2  2.3  1.2  1.2  
Anticonvulsants . . . . . . . . . . . . . . . . . . . .  2,093  0.8  .  .  .  2.1  0.7  2.5  1.2  0.6  
Oncolytics . . . . . . . . . . . . . . . . . . . . . . . . .  2,079  1.0  .  .  .  3.7  1.7  6.4  2.7  0.3  
Antineoplastics, miscellaneous . . . . . . . . . . .  1,078  0.5  .  .  .  .  .  .  1.6  7.5  3.1  0.4  
Hormonal and biological response modulators . 563 0.3 . . . . . . 4.0 7.5 1.9 0.5 
Antimetabolites  . . . . . . . . . . . . . . . . . . . .  484  0.2  .  .  .  .  .  .  .  .  .  9.6  3.6  .  .  .  
Antibiotics, alkaloids, and enzymes . . . . . . . .  103  0.1  .  .  .  .  .  .  .  .  .  8.8  7.0  .  .  .  
DNA  damaging  drugs  . . . . . . . . . . . . . . . .  396  0.2  .  .  .  .  .  .  .  .  .  8.9  7.5  .  .  .  
Ophthalmics. . . . . . . . . . . . . . . . . . . . . . . .  3,828  1.9  .  .  .  1.8  3.3  1.6  1.0  0.6  
Glaucoma. . . . . . . . . . . . . . . . . . . . . . . .  1,387  0.7  .  .  .  2.1  3.0  1.3  1.3  0.2  
Cycloplegics  and  mydriatics  . . . . . . . . . . . .  434  0.2  .  .  .  .  .  .  6.0  .  .  .  3.8  3.3  
Ocular anti-infective and anti-inflammatory . . . 1,739 0.9 . . . 2.7 4.0 2.3 1.0 0.7 
Miscellaneous ophthalmics . . . . . . . . . . . . .  1,476  0.7  .  .  .  2.7  4.9  .  .  .  1.2  1.4  
Decongestants and antiallergy agents . . . . . .  354  0.2  .  .  .  8.4  8.7  .  .  .  1.2  0.8  
Otics  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1,326  0.6  .  .  .  2.3  0.8  1.7  0.9  1.9  
Otic, topical (miscellaneous) . . . . . . . . . . . .  419  0.2  .  .  .  3.4  2.0  .  .  .  1.6  1.4  
Vertigo, motion sickness, and vomiting . . . . . .  1,141  0.5  .  .  .  2.4  0.8  2.0  0.9  2.1  
Relief  of  pain  . . . . . . . . . . . . . . . . . . . . . . .  10,853  2.9  .  .  .  1.7  0.9  1.5  0.8  1.1  
General analgesics . . . . . . . . . . . . . . . . . .  672  0.3  .  .  .  4.8  2.9  4.8  1.1  1.4  
Narcotic analgesics . . . . . . . . . . . . . . . . . .  3,214  1.4  .  .  .  1.8  1.2  1.9  1.0  1.5  
Non-narcotic analgesics . . . . . . . . . . . . . . .  4,118  1.3  .  .  .  2.4  0.6  1.7  1.1  1.3  
Antimigraine and other headaches . . . . . . . .  518  0.3  .  .  .  3.1  .  .  .  2.3  1.4  0.5  
Antiarthritics  . . . . . . . . . . . . . . . . . . . . . .  4,078  1.3  .  .  .  2.8  1.3  2.3  1.0  0.6  
Antigout . . . . . . . . . . . . . . . . . . . . . . . . .  547  0.2  .  .  .  5.2  .  .  .  5.3  1.1  0.6  
NSAID6 . . . . . . . . . . . . . . . . . . . . . . . . .  4,519  1.6  .  .  .  2.0  1.1  1.5  0.8  1.2  
Antipyretics  . . . . . . . . . . . . . . . . . . . . . . .  3,948  1.3  .  .  .  2.4  0.6  1.7  1.1  1.3  
Antiparasitics  . . . . . . . . . . . . . . . . . . . . . . .  618  0.3  .  .  .  3.4  0.8  2.7  1.6  0.9  
Antiprotozoals . . . . . . . . . . . . . . . . . . . . .  551  0.3  .  .  .  3.8  0.8  2.5  1.7  1.2  
Scabicides and pediculicides . . . . . . . . . . . .  113  0.1  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  
Antimalarials  . . . . . . . . . . . . . . . . . . . . . .  267  0.1  .  .  .  6.5  .  .  .  6.6  2.7  0.7  
Respiratory tract . . . . . . . . . . . . . . . . . . . . .  11,629  4.1  .  .  .  2.3  0.5  2.6  0.9  0.7  
Antiasthmatics and bronchodilators . . . . . . . .  5,085  2.1  .  .  .  3.0  0.5  3.6  1.0  0.8  
Nasal decongestants . . . . . . . . . . . . . . . . .  1,511  0.7  .  .  .  3.1  1.7  1.5  1.5  0.9  
Antitussives, expectorants. and mucolytics . . . 2,140 1.0 . . . 2.5 1.0 1.3 1.6 0.8 
Antihistamines  . . . . . . . . . . . . . . . . . . . . .  4,110  1.5  .  .  .  2.4  0.5  2.4  0.8  1.0  
Cold  remedies  . . . . . . . . . . . . . . . . . . . . .  1,185  0.6  .  .  .  4.3  1.2  .  .  .  1.9  1.2  
Corticosteroid - inhalation and nasal . . . . . . .  2,160  0.9  .  .  .  3.2  1.3  3.6  1.2  0.2  
Unclassified and miscellaneous. . . . . . . . . . . .  2,795  1.2  .  .  .  2.7  1.3  2.4  0.8  1.2  
Unclassified . . . . . . . . . . . . . . . . . . . . . .  2,662  1.2  .  .  .  2.9  1.4  2.7  0.8  1.0  
Pharmaceutical aids . . . . . . . . . . . . . . . . .  448  0.2  .  .  .  .  .  .  1.3  .  .  .  1.4  5.5  
Surgical  aids  . . . . . . . . . . . . . . . . . . . . . .  353  0.2  .  .  .  .  .  .  .  .  .  .  .  .  1.5  11.9  
Homeopathic products . . . . . . . . . . . . . . . . .  757  0.3  .  .  .  5.3  2.3  4.7  1.3  0.3  
* Figure does not meet standard of reliability or precision. . . . Category not applicable. 0.0 Quantity more than zero, but less than 0.05.

1Based on the standard drug classification used in the National Drug Code Directory, 1995 edition (12). In the NDC, therapeutic classes are assigned to drugs using 21 broad categories (2-digit level),

and into specific categories (4-digit level) within each broad group. In NAMCS and NHAMCS, up to three therapeutic classes can be coded for each drug. Drugs are counted in each class in which 
they occur. 
2Total of all therapeutic classes will exceed total number of drug mentions because up to three classes may be coded for each drug. 
3Based on an estimated annual average of 1,947,870,000 drug mentions at ambulatory care visits in 2003–04. 
4ACE is angiotensin converting enzyme. 
5CNS is central nervous system. 
6NSAID is nonsteroidal anti-inflammatory drug. 
NOTES: Numbers may not add to totals because of rounding and because subcategories with fewer than 30 records were omitted. Figures are annual averages. 
Page 24 [ Series 13, No. 163 
Table 8. Annual number and percent distribution of the 50 most frequently occurring generic equivalents at ambulatory care visits, with 
therapeutic class and corresponding standard errors: United States, 2003–04 
Number of Standard Standard 
mentions error in Percent error of 
Generic substance in thousands thousands distribution percent Specific therapeutic class1 
All  drug  mentions  . . . . . . . . . . . . . . . . . .  1,947,870 72,398 100.0 . . . . . . 
Ibuprofen . . . . . . . . . . . . . . . . . . . . . . .  41,039  2,152  2.1  0.1  NSAID2 
Aspirin. . . . . . . . . . . . . . . . . . . . . . . . .  39,597  3,268  2.0  0.1  Non-narcotic  analgesics; antiarthritics; antipyretics 
Atorvastatin calcium . . . . . . . . . . . . . . . .  32,643  2,422  1.7  0.1  Hyperlipidemia 
Acetaminophen . . . . . . . . . . . . . . . . . . .  31,694  1,878  1.6  0.1  Non-narcotic  analgesics; antipyretics 
Albuterol  . . . . . . . . . . . . . . . . . . . . . . .  30,039  1,858  1.5  0.1  Antiasthmatics  and  bronchodilators 
Acetaminophen with hydrocodone . . . . . . . .  28,984  1,515  1.5  0.1  Narcotic  analgesics 
Amoxicillin . . . . . . . . . . . . . . . . . . . . . .  25,964  1,741  1.3  0.1  Penicillins 
Levothyroxine . . . . . . . . . . . . . . . . . . . .  24,019  1,705  1.2  0.1  Thyroid and antithyroid 
Furosemide. . . . . . . . . . . . . . . . . . . . . .  22,289  1,638  1.1  0.1  Diuretics  
Metoprolol  . . . . . . . . . . . . . . . . . . . . . .  22,063  1,440  1.1  0.1  Beta  blockers 
Lisinopril . . . . . . . . . . . . . . . . . . . . . . .  19,992  1,632  1.0  0.1  ACE3 inhibitors 
Azithromycin  . . . . . . . . . . . . . . . . . . . . .  19,427  1,283  1.0  0.1  Lincosamides and macrolides 
Hydrochlorothiazide. . . . . . . . . . . . . . . . .  18,604  1,262  1.0  0.0  Diuretics  
Atenolol . . . . . . . . . . . . . . . . . . . . . . . .  18,106  1,429  0.9  0.1  Beta  blockers 
Prednisone . . . . . . . . . . . . . . . . . . . . . .  16,616  1,638  0.9  0.1  Adrenal corticosteroids 
Metformin  . . . . . . . . . . . . . . . . . . . . . . .  15,685  1,199  0.8  0.0  Blood  glucose regulators 
Fluticasone propionate . . . . . . . . . . . . . . .  15,568  1,108  0.8  0.0  Topical  steroids;  corticosteroid - inhalation and nasal 
Amlodipine  . . . . . . . . . . . . . . . . . . . . . .  15,060  1,072  0.8  0.0  Calcium  channel blockers 
Naproxen . . . . . . . . . . . . . . . . . . . . . . .  14,975  899  0.8  0.0  NSAID2 
Simvastatin . . . . . . . . . . . . . . . . . . . . . .  14,891  1,246  0.8  0.0  Hyperlipidemia 
Promethazine . . . . . . . . . . . . . . . . . . . .  14,378  821  0.7  0.0  Antihistamines; vertigo, motion sickness, and vomiting; 
sedatives and hypnotics 
Amoxicillin with clavulanate . . . . . . . . . . . .  14,136  1,040  0.7  0.1  Penicillins 
Warfarin sodium . . . . . . . . . . . . . . . . . . .  13,858  1,114  0.7  0.0  Anticoagulants and thrombolytics 
Cetirizine  . . . . . . . . . . . . . . . . . . . . . . .  13,778  1,390  0.7  0.1  Antihistamines  
Celecoxib . . . . . . . . . . . . . . . . . . . . . . .  13,236  944  0.7  0.0  Antiarthritics;  NSAID2 
Lansoprazole. . . . . . . . . . . . . . . . . . . . .  12,905  974  0.7  0.0  Acid  and  peptic disorders 
Cephalexin . . . . . . . . . . . . . . . . . . . . . .  12,755  695  0.7  0.0  Cephalosporins 
Fluticasone with salmeterol . . . . . . . . . . . .  12,682  1,162  0.7  0.1  Antiasthmatics  and  bronchodilators 
Rofecoxib . . . . . . . . . . . . . . . . . . . . . . .  12,515  941  0.6  0.0  NSAID2 
Sertraline . . . . . . . . . . . . . . . . . . . . . . .  12,416  816  0.6  0.0  Antidepressants 
Alprazolam . . . . . . . . . . . . . . . . . . . . . .  12,307  877  0.6  0.0  Antianxiety agents 
Fexofenadine . . . . . . . . . . . . . . . . . . . .  12,113  1,044  0.6  0.0  Antihistamines  
Montelukast sodium . . . . . . . . . . . . . . . .  11,952  1,222  0.6  0.1  Antiasthmatics  and  bronchodilators 
Triamcinolone  . . . . . . . . . . . . . . . . . . . .  11,664  874  0.6  0.0  Topical  steroids;  corticosteroid - nasal and inhalation; 
antiasthmatics and bronchodilators 
Paroxetine hydrochloride . . . . . . . . . . . . .  11,394  758  0.6  0.0  Antidepressants 
Escitalopram oxalate . . . . . . . . . . . . . . . .  11,151  879  0.6  0.0  Antidepressants 
Influenza virus vaccine. . . . . . . . . . . . . . .  10,478  1,787  0.5  0.1  Vaccines and antisera 
Esomeprazole magnesium . . . . . . . . . . . .  10,280  978  0.5  0.0  Acid  and  peptic disorders 
Fluoxetine hydrochloride. . . . . . . . . . . . . .  10,064  676  0.5  0.0  Antidepressants 
Lidocaine . . . . . . . . . . . . . . . . . . . . . . .  9,969  1,114  0.5  0.1  Anesthetics, topical; anesthetics, local (injectable); 
antiarrhythmic agents 
Pantoprazole sodium . . . . . . . . . . . . . . . .  9,932  931  0.5  0.0  Acid  and  peptic disorders 
Potassium replacement solutions . . . . . . . .  9,924  805  0.5  0.0  Replenishers and regulators of electrolytes and water 
balance 
Methylprednisolone . . . . . . . . . . . . . . . . .  9,783  737  0.5  0.0  Adrenal corticosteroids 
Insulin  . . . . . . . . . . . . . . . . . . . . . . . . .  9,453  853  0.5  0.0  Blood  glucose regulators 
Acetaminophen with oxycodone . . . . . . . . .  9,401  749  0.5  0.0  Narcotic  analgesics 
Ketorolac  tromethamine  . . . . . . . . . . . . . .  9,203  519  0.5  0.0  NSAID2 
Bupropion. . . . . . . . . . . . . . . . . . . . . . .  9,203  642  0.5  0.0  Antidepressants; pharmaceutical aids 
Estrogens. . . . . . . . . . . . . . . . . . . . . . .  9,106  825  0.5  0.0  Estrogens and progestins 
Diphenhydramine . . . . . . . . . . . . . . . . . .  8,988  611  0.5  0.0  Antihistamines  
Sulfamethoxazole with trimethoprim. . . . . . .  8,856  765  0.5  0.0  Sulfonamides and trimethoprim 
All  other  . . . . . . . . . . . . . . . . . . . . . . .  1,142,735 41,636 58.7 0.0 . . . 
. . . Category not applicable. 
0.0 Quantity more than zero, but less than 0.05.

1Based on the standard drug classification used in the National Drug Code Directory, 1995 edition (NDC) (12). In the NDC, therapeutic classes are assigned to drugs using 21 broad categories (2-digit

level), and into specific categories (4-digit level) within each broad group. In NAMCS and NHAMCS, up to three therapeutic classes can be coded for each drug. Drugs are counted in each class in

which they occur.

2NSAID is nonsteroidal anti-inflammatory drug.

3ACE is angiotensin converting enzyme.

NOTES: Numbers may not add to totals due to rounding. Figures are annual averages. 
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Table 9. Annual number and percent distribution of the generic equivalents most frequently provided, prescribed, or continued at 
ambulatory care visits, by setting type, with corresponding standard errors: United States, 2003–04 
Number of Standard Standard 
drug mentions error in Percent error of 
Selected characteristic in thousands thousands distribution percent Specific therapeutic class1 
Primary care offices 
All  drug  mentions  . . . . . . . . . . . . . . . . . .  975,895 50,268 100.0 . . . . . . 
Atorvastatin calcium . . . . . . . . . . . . . . . .  20,630  1,912  2.1  0.1  Hyperlipidemia 
Aspirin. . . . . . . . . . . . . . . . . . . . . . . . .  19,084  2,503  2.0  0.2  Non-narcotic  analgesics; antiarthritics; antipyretics 
Amoxicillin . . . . . . . . . . . . . . . . . . . . . .  18,026  1,569  1.8  0.1  Penicillins 
Ibuprofen . . . . . . . . . . . . . . . . . . . . . . .  16,940  1,633  1.7  0.1  NSAID2 
Albuterol  . . . . . . . . . . . . . . . . . . . . . . .  15,866  1,297  1.6  0.1  Antiasthmatics  and  bronchodilators 
Levothyroxine . . . . . . . . . . . . . . . . . . . .  14,847  1,226  1.5  0.1  Thyroid and antithyroid 
Acetaminophen . . . . . . . . . . . . . . . . . . .  13,426  1,614  1.4  0.2  Non-narcotic  analgesics; antipyretics 
Azithromycin  . . . . . . . . . . . . . . . . . . . . .  12,783  1,216  1.3  0.1  Lincosamides and macrolides 
Lisinopril . . . . . . . . . . . . . . . . . . . . . . .  12,737  1,398  1.3  0.1  ACE3 inhibitors 
Hydrochlorothiazide. . . . . . . . . . . . . . . . .  12,077  1,082  1.2  0.1  Diuretics  
All  other  . . . . . . . . . . . . . . . . . . . . . . . .  819,479 41,805 84.1 0.4 . . . 
Surgical specialty offices 
All  drug  mentions  . . . . . . . . . . . . . . . . . .  147,946 10,949 100.0 . . . . . . 
Prednisolone . . . . . . . . . . . . . . . . . . . . .  4,255  703  2.9  0.4  Adrenal corticosteroids; ocular anti-infective and 
anti-inflammatory 
Acetaminophen with hydrocodone . . . . . . . .  3,835  652  2.6  0.4  Narcotic  analgesics 
Latanoprost. . . . . . . . . . . . . . . . . . . . . .  2,663  391  1.8  0.2  Glaucoma 
Celecoxib . . . . . . . . . . . . . . . . . . . . . . .  2,563  411  1.7  0.2  Antiarthritics;  NSAID2 
Rofecoxib . . . . . . . . . . . . . . . . . . . . . . .  2,214  344  1.5  0.2  NSAID2 
Dexamethasone with tobramycin . . . . . . . .  2,022  456  1.4  0.3  Ocular  anti-infective  and  anti-inflammatory  
Aspirin. . . . . . . . . . . . . . . . . . . . . . . . .  1,924  361  1.3  0.2  Non-narcotic  analgesics; antiarthritics; antipyretics 
Naproxen . . . . . . . . . . . . . . . . . . . . . . .  1,918  360  1.3  0.2  NSAID2 
Lidocaine . . . . . . . . . . . . . . . . . . . . . . .  1,899  291  1.3  0.2  Anesthetics, topical; anesthetics, local (injectable); 
antiarrhythmic agents 
Brimonidine. . . . . . . . . . . . . . . . . . . . . .  1,813  329  1.2  0.2  Unclassified 
All  other  . . . . . . . . . . . . . . . . . . . . . . . .  122,841 9,169 83.0 0.8 . . . 
Medical specialty offices 
All  drug  mentions  . . . . . . . . . . . . . . . . . .  445,540 36,163 100.0 . . . . . . 
Aspirin. . . . . . . . . . . . . . . . . . . . . . . . .  12,028  1,275  2.7  0.2  Non-narcotic  analgesics; antiarthritics; antipyretics 
Furosemide. . . . . . . . . . . . . . . . . . . . . .  7,743  1,065  1.7  0.2  Diuretics  
Atorvastatin calcium . . . . . . . . . . . . . . . .  7,593  988  1.7  0.1  Hyperlipidemia 
Metoprolol  . . . . . . . . . . . . . . . . . . . . . .  7,297  814  1.6  0.1  Beta  blockers 
Levothyroxine . . . . . . . . . . . . . . . . . . . .  5,757  1,035  1.3  0.2  Thyroid and antithyroid 
Prednisone . . . . . . . . . . . . . . . . . . . . . .  5,528  1,336  1.2  0.3  Adrenal corticosteroids 
Albuterol  . . . . . . . . . . . . . . . . . . . . . . .  5,385  1,193  1.2  0.2  Antiasthmatics  and  bronchodilators 
Warfarin sodium . . . . . . . . . . . . . . . . . . .  5,262  683  1.2  0.1  Anticoagulants and thrombolytics 
Sertraline . . . . . . . . . . . . . . . . . . . . . . .  4,692  477  1.1  0.1  Antidepressants 
Atenolol . . . . . . . . . . . . . . . . . . . . . . . .  4,680  648  1.1  0.1  Beta  blockers 
All  others  . . . . . . . . . . . . . . . . . . . . . . .  379,575 30,240 85.2 0.7 . . . 
Hospital outpatient departments 
All  drug  mentions  . . . . . . . . . . . . . . . . . .  164,578 15,408 100.0 . . . . . . 
Ibuprofen . . . . . . . . . . . . . . . . . . . . . . .  4,542  487  2.8  0.2  NSAID2 
Acetaminophen . . . . . . . . . . . . . . . . . . .  4,011  452  2.4  0.2  Non-narcotic  analgesics; antipyretics 
Albuterol  . . . . . . . . . . . . . . . . . . . . . . .  3,216  362  2.0  0.1  Antiasthmatics  and  bronchodilators 
Aspirin. . . . . . . . . . . . . . . . . . . . . . . . .  3,147  536  1.9  0.2  Non-narcotic  analgesics; antiarthritics; antipyretics 
Amoxicillin . . . . . . . . . . . . . . . . . . . . . .  2,861  390  1.7  0.2  Penicillins 
Atorvastatin calcium . . . . . . . . . . . . . . . .  2,347  371  1.4  0.1  Hyperlipidemia 
Hydrochlorothiazide. . . . . . . . . . . . . . . . .  2,109  253  1.3  0.1  Diuretics  
Acetaminophen with hydrocodone . . . . . . . .  1,967  286  1.2  0.1  Narcotic  analgesics 
Metoprolol  . . . . . . . . . . . . . . . . . . . . . .  1,938  276  1.2  0.1  Beta  blockers 
Azithromycin  . . . . . . . . . . . . . . . . . . . . .  1,730  209  1.1  0.1  Lincosamides and macrolides 
All  other  . . . . . . . . . . . . . . . . . . . . . . . .  136,710 12,960 83.0 0.6 . . . 
See footnotes at end of table. 
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Table 9. Annual number and percent distribution of the generic equivalents most frequently provided, prescribed, or continued at 
ambulatory care visits, by setting type, with corresponding standard errors: United States, 2003–04—Con. 
Number of Standard Standard 
drug mentions error in Percent error of 
Selected characteristic in thousands thousands distribution percent Specific therapeutic class1 
Hospital emergency departments 
All  drug  mentions  . . . . . . . . . . . . . . . . . .  213,909 9,218 100.0 . . . . . . 
Ibuprofen . . . . . . . . . . . . . . . . . . . . . . .  15,199  786  7.1  0.2  NSAID2 
Acetaminophen . . . . . . . . . . . . . . . . . . .  11,340  592  5.3  0.2  Non-narcotic  analgesics; antipyretics 
Acetaminophen with hydrocodone . . . . . . . .  11,050  601  5.2  0.2  Narcotic  analgesics 
Antihistamines; vertigo, motion sickness and vomiting; 
Promethazine . . . . . . . . . . . . . . . . . . . .  8,547  443  4.0  0.2  sedatives and hypnotics 
Ketorolac  tromethamine  . . . . . . . . . . . . . .  6,293  292  2.9  0.1  NSAID2 
Albuterol  . . . . . . . . . . . . . . . . . . . . . . .  5,030  253  2.4  0.1  Antiasthmatics  and  bronchodilators 
Morphine  . . . . . . . . . . . . . . . . . . . . . . .  4,662  252  2.2  0.1  Narcotic  analgesics 
Amoxicillin . . . . . . . . . . . . . . . . . . . . . .  3,626  246  1.7  0.1  Penicillins 
Azithromycin  . . . . . . . . . . . . . . . . . . . . .  3,473  197  1.6  0.1  Lincosamides and macrolides 
Aspirin. . . . . . . . . . . . . . . . . . . . . . . . .  3,415  239  1.6  0.1  Non-narcotic  analgesics; antiarthritics; antipyretics 
All  other  . . . . . . . . . . . . . . . . . . . . . . . .  141,275 6,441 66.0 0.5 . . . 
. . . Category not applicable.

1 Based on the standard drug classification used in the National Drug Code Directory, 1995 edition (NDC) (12). In the NDC, therapeutic classes are assigned to drugs using 21 broad categories (2-digit

level), and into specific categories (4-digit level) within each broad group. In NAMCS and NHAMCS, up to three therapeutic classes can be coded for each drug. Drugs are counted in each class in

which they occur.

2NSAID is nonsteroidal anti-inflammatory drug.

3ACE is angiotensin converting enzyme.

NOTES: Numbers may not add to totals due to rounding. Figures are annual averages.
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Table 10. Annual population rates for the top 20 specific therapeutic classes of drug mentions at ambulatory care visits, by patient age and 
sex: United States, 2003–04 
Patient age in years Sex 
75 
Specific therapeutic class1 Total Under 15 15–24 25–44 45–64 65–74 or more Female Male 
Number of occurrences per 1,000 persons2 
NSAID3 . . . . . . . . . . . . . . . . . . . . . . . . . .  390.3 242.1 259.4 349.3 482.6 696.0 742.2 440.3 337.9 
Antidepressants . . . . . . . . . . . . . . . . . . . . .  310.9 65.4 175.4 310.8 492.4 492.7 587.3 410.4 206.8 
Antiasthmatics and bronchodilators . . . . . . . . .  278.0 335.8 126.2 155.8 336.4 510.1 548.2 311.8 242.6 
Antihistamines  . . . . . . . . . . . . . . . . . . . . . .  276.9 301.4 199.5 243.9 302.7 390.5 307.1 339.2 211.6 
Narcotic analgesics . . . . . . . . . . . . . . . . . . .  273.5 36.9 185.8 332.7 389.1 391.1 451.5 317.6 227.4 
Non-narcotic analgesics . . . . . . . . . . . . . . . .  266.6 223.9 90.5 114.7 294.8 690.5 1,034.0 280.1 252.3 
Antipyretics  . . . . . . . . . . . . . . . . . . . . . . . .  243.7 222.6 84.0 92.8 255.8 644.6 980.6 248.6 238.6 
Antihypertensive agents . . . . . . . . . . . . . . . .  242.5 *2.6 *11.6 65.4 406.2 848.0 1,230.0 273.4 210.3 
Hyperlipidemia . . . . . . . . . . . . . . . . . . . . . .  241.7 *3.7 *4.8 50.0 429.3 983.6 1,058.0 238.4 245.1 
Acid and peptic disorders . . . . . . . . . . . . . . .  237.4 41.5 53.3 146.5 359.3 676.1 876.1 271.1 202.3 
Antiarthritics. . . . . . . . . . . . . . . . . . . . . . . .  232.6 *6.4 26.6 95.4 354.8 829.8 1,094.0 243.7 221.0 
Blood glucose regulators . . . . . . . . . . . . . . . .  207.5 *11.2 20.2 69.1 374.4 760.3 775.0 216.1 198.5 
Vaccines and antisera . . . . . . . . . . . . . . . . .  192.0 601.3 59.1 55.0 73.4 179.6 205.4 188.3 195.9 
Diuretics  . . . . . . . . . . . . . . . . . . . . . . . . . .  176.4 4.8 *5.3 40.4 243.8 628.2 1,134.0 207.6 143.6 
Vitamins  and  minerals  . . . . . . . . . . . . . . . . .  173.5 54.3 95.4 117.0 199.6 424.7 704.6 236.4 107.6 
ACE4 inhibitors  . . . . . . . . . . . . . . . . . . . . . .  173.2 *4.1 *4.0 47.7 273.5 636.1 912.8 175.6 170.8 
Beta blockers . . . . . . . . . . . . . . . . . . . . . . .  161.9 4.5 11.4 42.1 234.0 625.7 901.2 180.6 142.4 
Penicillins . . . . . . . . . . . . . . . . . . . . . . . . .  156.3 382.5 119.0 99.3 83.5 81.8 85.0 160.9 151.4 
Adrenal corticosteroids . . . . . . . . . . . . . . . . .  141.7 125.4 65.2 95.2 173.3 294.7 320.5 150.8 132.1 
Anticonvulsants. . . . . . . . . . . . . . . . . . . . . .  131.3 38.2 69.2 138.1 193.8 214.0 239.2 154.8 106.7 
Standard error of rate 
NSAID3 . . . . . . . . . . . . . . . . . . . . . . . . . .  15.7  23.7  14.7  16.0  25.8  52.3  57.8  18.6  15.3  
Antidepressants . . . . . . . . . . . . . . . . . . . . .  14.3  8.2  13.2  15.9  26.7  51.3  53.5  20.0  11.7  
Antiasthmatics and bronchodilators . . . . . . . . .  17.7  29.5  11.5  15.0  28.1  53.7  60.4  21.1  17.4  
Antihistamines  . . . . . . . . . . . . . . . . . . . . . .  14.3  26.9  14.8  14.7  18.3  37.5  34.7  18.6  12.0  
Narcotic analgesics . . . . . . . . . . . . . . . . . . .  11.2  3.0  11.8  15.8  18.5  35.5  32.3  13.7  10.1  
Non-narcotic analgesics . . . . . . . . . . . . . . . .  14.4  23.6  5.8  6.7  22.3  55.1  84.6  14.7  15.9  
Antipyretics  . . . . . . . . . . . . . . . . . . . . . . . .  13.8  23.8  5.6  6.4  21.1  51.6  80.3  13.8  15.4  
Antihypertensive agents . . . . . . . . . . . . . . . .  15.1  1.0  4.1  6.1  30.9  64.3  102.9 18.3 15.0 
Hyperlipidemia . . . . . . . . . . . . . . . . . . . . . .  15.5  1.4  2.0  5.4  29.4  70.5  96.7  16.6  17.4  
Acid and peptic disorders . . . . . . . . . . . . . . .  13.1  6.9  5.5  8.7  23.3  54.8  74.7  15.7  12.9  
Antiarthritics. . . . . . . . . . . . . . . . . . . . . . . .  14.2  2.1  3.8  6.7  27.6  60.1  89.8  14.0  16.4  
Blood glucose regulators . . . . . . . . . . . . . . . .  14.4  4.5  4.9  7.9  30.1  80.7  68.2  17.5  15.5  
Vaccines and antisera . . . . . . . . . . . . . . . . .  12.6  51.2  6.3  6.6  9.0  35.8  39.1  14.4  14.2  
Diuretics  . . . . . . . . . . . . . . . . . . . . . . . . . .  10.5  1.3  1.7  4.0  17.2  48.3  89.1  14.0  9.9  
Vitamins  and  minerals  . . . . . . . . . . . . . . . . .  11.8  9.2  18.1  13.3  19.5  47.3  75.3  17.7  8.4  
ACE4 inhibitors  . . . . . . . . . . . . . . . . . . . . . .  10.5  1.3  1.2  5.4  19.5  46.8  70.4  11.6  11.2  
Beta blockers . . . . . . . . . . . . . . . . . . . . . . .  9.6  1.1  2.8  4.1  17.5  46.4  70.1  10.7  10.4  
Penicillins . . . . . . . . . . . . . . . . . . . . . . . . .  8.6  27.7  10.2  7.3  7.3  14.6  13.5  9.2  9.4  
Adrenal corticosteroids . . . . . . . . . . . . . . . . .  7.4  10.5  6.3  8.2  13.3  29.4  32.6  8.8  8.1  
Anticonvulsants. . . . . . . . . . . . . . . . . . . . . .  7.3  6.4  6.7  9.6  13.5  26.9  27.2  9.5  6.9  
* Figure does not meet standard of reliability or precision.

1Based on the standard drug classification used in the National Drug Code Directory, 1995 edition (NDC) (12). In the NDC, therapeutic classes are assigned to drugs using 21 broad categories (2-digit

level), and into specific categories (4-digit level) within each broad group. In NAMCS and NHAMCS, up to three therapeutic classes can be coded for each drug. Drugs are counted in each class in 
which they occur. 
2Estimates of the civilian noninstitutionalized population used in computing visit rates by age and sex are from special tabulations developed by the Population Division, U.S. Census Bureau, using the 
July 1, 2003, and July 1, 2004, sets of state population estimates and reflect Census 2000 data.

3NSAID is non-steroidal anti-inflammatory drug.

4ACE is angiotensin converting enzyme.

NOTES: Figures are annual averages. 
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Table 11. Annual population rates for the top 20 specific therapeutic classes of drug mentions at ambulatory care visits, by selected patient 
and provider characteristics: United States, 2003–04 
Patient race Expected source of payment MSA2 status 
Private 
Specific therapeutic class1 Total White Black insurance Medicare Medicaid Uninsured MSA Not MSA 
Number of occurrences per 1,000 persons3 
NSAID4 . . . . . . . . . . . . . . . . . . .  390.3 392.1 474.1 289.7 616.8 535.9 186.0 392.2 379.4 
Antidepressants . . . . . . . . . . . . . .  310.9 344.5 207.0 237.7 564.8 345.9 174.1 318.9 269.0 
Antiasthmatics and bronchodilators . . 278.0 284.1 306.1 211.1 517.1 451.3 89.1 285.8 237.6 
Antihistamines  . . . . . . . . . . . . . . .  276.9 283.7 275.0 244.2 332.9 389.4 107.0 282.4 246.2 
Narcotic analgesics . . . . . . . . . . . .  273.5 284.1 299.4 179.5 445.5 400.3 201.8 268.7 299.2 
Non-narcotic analgesics . . . . . . . . .  266.6 266.8 315.3 158.3 737.9 400.2 93.3 260.7 296.9 
Antipyretics  . . . . . . . . . . . . . . . . .  243.7 242.6 293.5 144.8 683.7 365.0 81.3 240.2 262.0 
Antihypertensive agents . . . . . . . . .  242.5 241.2 306.7 157.0 877.9 117.1 52.3 245.1 228.6 
Hyperlipidemia . . . . . . . . . . . . . . .  241.7 248.7 227.9 165.2 823.0 135.9 36.4 246.8 214.1 
Acid and peptic disorders . . . . . . . .  237.4 240.1 234.9 156.5 677.1 254.5 73.2 237.1 238.8 
Antiarthritics  . . . . . . . . . . . . . . . .  232.6 238.4 250.2 142.3 803.1 157.1 48.8 228.6 254.3 
Blood glucose regulators. . . . . . . . .  207.5 199.1 287.5 129.5 661.8 205.5 56.4 204.5 222.7 
Vaccines and antisera . . . . . . . . . .  192.0 195.3 175.9 158.0 162.3 443.2 42.8 206.4 117.2 
Diuretics . . . . . . . . . . . . . . . . . . .  176.4 176.2 236.3 83.4 755.2 119.7 43.4 173.9 188.6 
Vitamins  and  minerals  . . . . . . . . . .  173.5 181.8 151.3 116.7 490.2 203.1 45.4 177.1 156.3 
ACE5 inhibitors. . . . . . . . . . . . . . .  173.2 175.5 202.5 102.3 641.7 119.5 38.7 172.2 178.0 
Beta blockers. . . . . . . . . . . . . . . .  161.9 164.0 186.8 93.1 630.3 91.3 30.7 165.1 144.4 
Penicillins . . . . . . . . . . . . . . . . . .  156.3 155.0 164.2 137.7 101.6 312.2 67.8 159.1 141.6 
Adrenal corticosteroids . . . . . . . . . .  141.7 147.4 144.2 109.4 268.2 180.2 52.5 144.5 127.1 
Anticonvulsants . . . . . . . . . . . . . .  131.3 140.3 116.2 79.0 261.5 227.5 75.4 134.4 115.5 
Standard error of rate 
NSAID4 . . . . . . . . . . . . . . . . . . .  15.7  17.8  27.9  13.8  39.7  44.5  13.3  17.0  46.0  
Antidepressants . . . . . . . . . . . . . .  14.3  16.4  19.2  12.9  43.4  30.8  21.0  16.7  33.5  
Antiasthmatics and bronchodilators . . 17.7 19.7 29.5 17.3 47.8 37.8 8.5 20.5 28.7 
Antihistamines  . . . . . . . . . . . . . . .  14.3  16.0  21.3  14.5  26.0  35.2  8.1  16.7  30.3  
Narcotic analgesics . . . . . . . . . . . .  11.2  12.9  16.0  9.4  27.8  28.0  11.4  12.6  34.2  
Non-narcotic analgesics . . . . . . . . .  14.4  15.6  26.7  10.8  51.4  40.5  8.2  15.3  43.9  
Antipyretics  . . . . . . . . . . . . . . . . .  13.8  14.8  27.9  10.4  48.9  38.1  7.1  14.7  41.4  
Antihypertensive agents . . . . . . . . .  15.1  16.7  35.1  12.1  66.3  18.3  6.8  17.1  38.6  
Hyperlipidemia . . . . . . . . . . . . . . .  15.5  17.3  27.4  13.1  60.8  17.5  6.2  17.7  32.1  
Acid and peptic disorders . . . . . . . .  13.1  14.7  18.7  10.8  50.2  23.9  8.2  14.9  36.1  
Antiarthritics  . . . . . . . . . . . . . . . .  14.2  16.3  24.1  11.7  54.0  17.7  6.3  14.7  48.1  
Blood glucose regulators. . . . . . . . .  14.4  15.4  32.4  10.8  58.4  28.8  7.5  15.1  45.9  
Vaccines and antisera . . . . . . . . . .  12.6  13.9  18.4  13.2  29.3  50.0  5.8  14.2  22.6  
Diuretics . . . . . . . . . . . . . . . . . . .  10.5  11.4  22.5  6.9  54.9  13.6  6.4  11.6  30.9  
Vitamins  and  minerals  . . . . . . . . . .  11.8  13.5  18.6  9.7  46.2  29.2  6.5  13.4  26.9  
ACE5 inhibitors. . . . . . . . . . . . . . .  10.5  12.0  20.1  8.5  45.5  14.9  5.7  11.4  30.0  
Beta blockers. . . . . . . . . . . . . . . .  9.6  10.7  17.8  6.7  45.5  11.3  4.0  11.1  20.4  
Penicillins . . . . . . . . . . . . . . . . . .  8.6  9.0  14.6  8.8  13.5  28.1  6.3  9.7  19.8  
Adrenal corticosteroids . . . . . . . . . .  7.4  8.4  11.7  8.2  19.9  15.7  6.1  8.7  17.4  
Anticonvulsants . . . . . . . . . . . . . .  7.3  8.4  11.3  5.4  20.1  22.4  10.3  8.3  17.9  
1Based on the standard drug classification used in the National Drug Code Directory, 1995 edition (NDC) (12). In the NDC, therapeutic classes are assigned to drugs using 21 broad categories (2-digit

level), and into specific categories (4-digit level) within each broad group. In NAMCS and NHAMCS, up to three therapeutic classes can be coded for each drug. Drugs are counted in each class in

which they occur.

2MSA is metropolitan statistical area.

3Estimates of the civilian noninstitutionalized population used in computing rates by race are from special tabulations developed by the Population Division, U.S. Census Bureau, using the July 1, 2003,

and July 1, 2004, sets of state population estimates and reflect Census 2000 data. Denominators for primary expected source of payment rates are from the 2003 and 2004 estimates of health

coverage from the National Health Interview Survey, NCHS, adjusted to Census 2000-based population estimates. Denominators for metropolitan and nonmetropolitan statistical area rates are based

on data from the 2003 and 2004 National Health Interview Survey, NCHS, adjusted to the U.S. Census Bureau definition of core-based statistical areas as of December 2003.

4NSAID is nonsteroidal anti-inflammatory drug.

5ACE is angiotensin converting enzyme.

NOTES: Figures are annual averages. Races other than white and black are not shown because of small sample sizes.

Series 13, No. 163 [ Page 29 
Table 12. Annual percent distribution and rate of the generic-equivalents most frequently provided, prescribed, or continued at ambulatory 
care visits: United States, 1993–94 and 2003–04 
Number of 
Percent mentions per 
1993–94 distribution 100 visits Specific therapeutic class1 
All drugs. . . . . . . . . . . . . . . . . . .  100.0 128.8 . . .

Amoxicillin. . . . . . . . . . . . . . . . . .  3.3  4.3  Penicillins

Ibuprofen . . . . . . . . . . . . . . . . . .  2.2  2.8  NSAID2

Acetaminophen . . . . . . . . . . . . . .  2.1  2.7  Non-narcotic  analgesics; antipyretics

Albuterol. . . . . . . . . . . . . . . . . . .  1.8  2.4  Antiasthmatics  and  bronchodilators

Furosemide . . . . . . . . . . . . . . . . .  1.3  1.6  Diuretics 

Erythromycin  . . . . . . . . . . . . . . . .  1.2  1.5  Lincosamides and macrolides

Aspirin  . . . . . . . . . . . . . . . . . . . .  1.1  1.5  Non-narcotic  analgesics; antiarthritics; antipyretics

Prednisone . . . . . . . . . . . . . . . . .  1.1  1.4  Adrenal corticosteroids

Estrogens . . . . . . . . . . . . . . . . . .  1.1  1.4  Estrogens and progestins

Digoxin . . . . . . . . . . . . . . . . . . .  1.0  1.3  Cardiac glycosides

All other . . . . . . . . . . . . . . . . . . .  83.8  107.9 . . .

2003–04 
All drugs. . . . . . . . . . . . . . . . . . .  100.0 158.7 . . .

Ibuprofen . . . . . . . . . . . . . . . . . .  2.3  3.6  NSAID2

Aspirin  . . . . . . . . . . . . . . . . . . . .  1.8  2.8  Non-narcotic  analgesics; antiarthritics; antipyretics

Acetaminophen . . . . . . . . . . . . . .  1.7  2.7  Non-narcotic  analgesics; antipyretics

Atorvastatin calcium. . . . . . . . . . . .  1.6  2.5  Hyperlipidemia

Acetaminophen with hydrocodone . . . 1.6 2.5 Narcotic analgesics

Albuterol. . . . . . . . . . . . . . . . . . .  1.5  2.5  Antiasthmatics  and  bronchodilators

Amoxicillin. . . . . . . . . . . . . . . . . .  1.5  2.3  Penicillins

Levothyroxine . . . . . . . . . . . . . . .  1.2  1.9  Thyroid and antithyroid

Azithromycin  . . . . . . . . . . . . . . . .  1.1  1.7  Lincosamides and macrolides

Metoprolol. . . . . . . . . . . . . . . . . .  1.1  1.7  Beta blockers

All other . . . . . . . . . . . . . . . . . . .  84.6  134.5 . . .

. . . Category not applicable.

1Based on the standard drug classification used in the National Drug Code Directory, 1995 edition (NDC) (12). In the NDC, therapeutic classes are assigned to drugs using 21 broad categories (2-digit

level), and into specific categories (4-digit level) within each broad group. In NAMCS and NHAMCS, up to three therapeutic classes can be coded for each drug. Drugs are counted in each class in

which they occur.

2NSAID is nonsteroidal anti-inflammatory drug.

NOTE: For this table, 2003–04 data were limited to the first five out of eight possible drug entries for each sampled visit. This was done in order to be consistent with the 1993–94 data collection, in

which a maximum of five drugs could be coded.
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Technical Notes 
Data collection 
The National Ambulatory Medical 
Care Survey (NAMCS) and National 
Hospital Ambulatory Medical Care 
Survey (NHAMCS) data collection is 
authorized under Section 308(d) of the 
Public Health Service Act (42 United 
States Code Section 306 [242k]. 
Participation is voluntary. 
For the 2003 NAMCS, 3,000 
physicians were selected from the 
masterfiles of the American Medical 
Association and American Osteopathic 
Association. Of these, 2,007 were 
in-scope, or eligible to participate in the 
survey. Sampled physicians were asked 
to complete Patient Record forms 
(PRFs) for a systematic random sample 
of office visits occurring during a 
randomly assigned 1-week reporting 
period. A total of 1,407 physicians 
participated in the survey, 65 of them 
minimally (defined as submitting fewer 
than 50 percent of their expected 
number of PRFs). The physician 
response rate was 67 percent, and 
25,288 PRFs were submitted. Data were 
collected from December 30, 2002, 
through December 30, 2003. It should 
be noted that response rates for both 
NAMCS and NHAMCS do not include 
minimal responders. 
For the 2004 NAMCS, 1,961 
physicians of the 3,000 sampled were 
in-scope; 1,372 of them participated, 
103 of them at a minimal level. The 
physician response rate was 65 percent, 
and 25,286 PRFs were submitted; data 
collection occurred from December 29, 
2003, through December 26, 2004. 
NHAMCS utilizes a fixed panel of 
600 hospitals. To preclude hospitals 
participating during the same time 
period each year, the sample was 
randomly divided into 16 subsets of 
approximately equal size. Each subset 
was assigned to 1 of 16 4-week 
reporting periods beginning December 2, 
1991, which continue to rotate across 
each survey year. Therefore, the entire sample does not participate in a given 
year, and each hospital is inducted 
approximately once every 15 months. 
Hospital staff were asked to complete 
PRFs for a systematic random sample of 
patient visits occurring during a 
randomly assigned 4-week reporting 
period. 
The 2003 NHAMCS collected data 
from December 30, 2002, through 
December 28, 2003, and consisted of a 
sample of 546 hospitals, of which 443 
had eligible EDs. Of these, 406 EDs 
participated, 1 of them minimally, for an 
unweighted ED participation rate of 
91 percent. Of the 506 emergency 
service areas (ESAs) selected from the 
emergency departments, 475 provided 
data, 3 of them at a minimal level. The 
ESA response rate was 93 percent, and 
the overall ED response rate was 
85 percent. In all, 40,253 ED PRFs were 
collected. 
Of the 546 hospitals sampled in 
2003, 272 had eligible outpatient 
departments. Of these 236 participated, 
10 at a minimal level, for an unweighted 
OPD participation rate of 83 percent. Of 
the 1,087 clinics selected from the 
in-scope OPDs, 983 participated, 35 at a 
minimal level. The clinic response rate 
was 87 percent, for an overall OPD 
response rate of 73 percent. In all, 
34,492 OPD PRFs were collected. 
The 2004 NHAMCS collected data 
from December 29, 2003, through 
December 26, 2004, and consisted of a 
sample of 464 hospitals, of which 397 
were in scope and had eligible EDs. Of 
these, 365 EDs participated, for an 
unweighted ED response rate of 
92 percent. Of the 467 ESAs selected 
from the EDs, 457 provided data, 5 of 
them minimally, and 1 ESA saw no 
patients during the reporting period but 
was counted as a respondent. The ESA 
response rate was 97 percent, and the 
overall ED response rate was 89 percent. 
In all, 36,589 ED PRFs were collected. 
Of the 464 hospitals sampled in 
2004, 250 had eligible OPDs, of which 
217 participated, for an unweighted 
OPD participation rate of 87 percent. Of 
the 1,108 clinics selected from the 
OPDs, 984 provided data, 29 of them at 
a minimal level. An additional 6 
responding clinics saw no patients during the reporting period. The clinic 
response rate was 87 percent, for an 
overall OPD response rate of 75 percent. 
In all, 31,783 OPD PRFs were collected. 
The U.S. Census Bureau, acting as 
the data collection agent for both 
surveys, provided training to field 
representatives (FRs) throughout the 
Nation who, in turn, oversaw data 
collection at physician offices and 
hospitals. FRs contacted physicians and 
hospitals for induction into the surveys 
after NCHS mailed an advance letter 
notifying the providers of their selection 
in the survey. For the NAMCS, medical 
staff most often provided the 
information requested on the PRFs 
(Appendix III); however, in some cases, 
FRs performed data abstraction from 
medical records. For the NHAMCS, FR 
abstraction was the predominant method 
of data collection. Neither the patient’s 
name nor address was collected. 
Confidentiality of the data collected in 
the survey is protected under the 
Privacy Act, Public Health Service Act, 
and Title 42 of the United States Code, 
Section 242m(d). 
Estimation 
Estimates from the 2003 and 2004 
NAMCS and NHAMCS were derived 
by multistage estimation procedures that 
produce essentially unbiased estimates. 
The estimation for NAMCS has four 
basic components: 1) inflation by 
reciprocals of the probabilities of 
selection; 2) adjustment for 
nonresponse; 3) a ratio adjustment to 
fixed totals; and 4) weight smoothing. 
These are described in more detail 
elsewhere (20,21). However, certain 
changes were made to the NAMCS and 
NHAMCS nonresponse adjustments in 
2003 and 2004; these changes are 
described below. 
Estimates from NAMCS data are 
typically adjusted to account for sample 
physicians who were in scope but did 
not participate in the study. This 
adjustment is calculated to minimize the 
impact of nonresponse on final 
estimates. The weights of visits for 
physicians similar to the nonrespondent 
physicians are inflated to account for 
visits represented by the nonrespondent 
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were judged similar if they had the 
same specialty designation and practiced 
in the same primary sampling unit (2). 
Beginning with 2003 data, the 
adjustment for nonresponding physicians 
differs from the adjustment used in prior 
years. Previously the adjustment 
accounted for nonresponse by physician 
specialty, geographic region, and 
metropolitan statistical area status. The 
revised nonresponse adjustment also 
accounts for nonresponse from 
physicians by practice size, as measured 
by number of weekly visits, and for 
variability in number of weeks that 
participating physicians saw patients 
during the year. 
Previously, these characteristics 
were assumed to be the same for 
physicians providing patient encounter 
information and those not providing 
such information. However, research 
done for the first time with 2003 data 
showed that these two assumptions are 
not always true. In general, the weekly 
visit volume for non-PRF physicians 
was larger than for PRF physicians. 
Also, physicians who saw no patients 
during their sample week tended to see 
patients fewer weeks annually than did 
physicians who saw patients during their 
week. To minimize understatement (and 
in some cases, overstatement) of visits, 
the nonresponse adjustment factor was 
revised to include information on the 
number of weeks physicians actually 
practiced during a typical year and the 
number of visits physicians reported 
during a week. Both data items were 
collected for responding and 
nonresponding physicians during the 
induction interview starting with the 
2001 survey. 
The 2003 weight with the revised 
nonresponse adjustment increased the 
overall visit estimate by 12 percent over 
the same estimate obtained using the 
original weight. For this reason, 2003 
and 2004 visit estimates are not 
comparable to visit estimates computed 
using the previous weighting strategy. 
For more information, including 
recommendations for researchers 
analyzing trend data, please see the 
2003 NAMCS summary (2). 
Beginning with 2004 data, changes 
were made to the nonresponse adjustment factor to account for the 
seasonality of the reporting period. Extra 
weights for nonresponding physicians 
were shifted to responding physicians in 
reporting periods within the same 
quarter of the year. The shift in 
nonresponse adjustment did not 
significantly affect any of the overall 
annual estimates. 
The estimation for NHAMCS has 
three basic components: 1) inflation by 
reciprocals of the sampling selection 
probabilities; 2) adjustment for 
nonresponse; and 3) a population 
weighting ratio adjustment. The 
population weighting ratio adjustment 
for OPD estimates was replaced by an 
adjustment which controls for effects of 
rotating hospital sample panels into and 
out of the sample each year. (The full 
NHAMCS hospital sample is partitioned 
into 16 panels that are rotated into the 
sample over 16 periods of 4 weeks each 
so that only 13 panels are used in any 
single year.) The sampling weights of 
some OPDs were permanently trimmed 
to prevent single OPDs from 
contributing more than 15 percent of 
their region’s total to OPD visit 
estimates. 
NHAMCS data were adjusted to 
account for two types of nonresponse. 
The first type occurred when a hospital 
refused to provide information about its 
ED or OPD that was publicly known to 
exist. In this case, the weights of visits 
to hospitals similar to the nonrespondent 
hospitals were inflated to account for 
visits represented by the nonrespondent 
hospitals. Beginning with 1998 data, 
hospitals were judged to be similar if 
they were in the same region and, 
except in the West, if they had the same 
MSA status (in an MSA vs. not in an 
MSA). Similarity of hospitals also 
required being in the same ownership 
control group (voluntary nonprofit 
compared with other). This adjustment 
was made separately by department 
type. 
The second type of nonresponse 
occurred when a sample ESA within a 
respondent hospital failed to provide 
completed PRFs for a sample of patient 
visits. In the ED, the weights of visits 
from responding ESAs were inflated to 
account for visits to similar 
nonresponding ESAs, where ESAs were judged to be similar if they were in the 
same region. Except in the West, ESA 
similarity also required having the same 
MSA status, and, in MSAs, being in the 
same ownership control group 
(voluntary nonprofit vs. other). 
For the OPD, weights of visits from 
responding OPD clinics were inflated to 
account for visits to similar 
nonresponding OPD clinics, where OPD 
clinics were judged to be similar if they 
were in the same region, clinic type, and 
ownership control group (voluntary 
nonprofit vs. other). There were six 
OPD clinic types: general medicine, 
pediatrics, surgery, obstetrics and 
gynecology, alcohol and/or substance 
abuse, and other OPD clinic. Beginning 
with 1998 data, formation of groups of 
similar clinics also considered the MSA 
status of the clinic (in an MSA or not in 
an MSA) with the following two 
exceptions: in the West, MSA status was 
not considered; and in non-MSA clinics 
in the other three regions, ownership 
control group (voluntary nonprofit 
compared with other) was not 
considered. 
Beginning with 2004 data, changes 
were made to the nonresponse 
adjustment factor to account for the 
seasonality of the reporting period. Extra 
weights for nonresponding hospital 
OPDs and EDs were shifted to 
responding OPDs and EDs in reporting 
periods within the same quarter of the 
year. The shift in nonresponse 
adjustment did not significantly affect 
any of the overall annual estimates. 
Sampling Errors 
The standard error is primarily a 
measure of the sampling variability that 
occurs by chance when only a sample, 
rather than an entire universe, is 
surveyed. The standard error also 
reflects part of the measurement error, 
but does not measure any systematic 
biases in the data. The chances are 95 
out of 100 that an estimate from the 
sample differs from the value that would 
be obtained from a complete census by 
less than twice the standard error. 
The standard errors used in tests of 
significance for this report were 
calculated using SUDAAN software. 
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using a first-order Taylor approximation 
of the deviation of estimates from their 
expected values. A description of the 
software and the approach it uses has 
been published (19). The relative 
standard error (RSE) of an estimate is 
obtained by dividing the standard error 
by the estimate itself. The result is then 
expressed as a percent of the estimate. 
It is recommended that statistical 
software (such as SUDAAN, SAS, 
SPSS, or Stata) be used to compute 
variances for complex survey data. 
When it is not feasible to use statistical 
software, one may calculate approximate 
RSEs for aggregate estimates using 
generalized variance curve parameters as 
described in the NAMCS and NHAMCS 
public use file documentation (20,21). 
These publications contain information 
for computing approximate RSEs for 
single years of NAMCS and NHAMCS 
data from 2003 and 2004. For estimates 
based on two or more years of data, or 
when combining data from multiple 
settings across one or more years, please 
consult the Ambulatory Care Statistics 
Branch at 301-458-4600 for more 
information about approximating RSEs 
using generalized variance curves. 
Nonsampling errors 
As in any survey, results are subject 
to both sampling and nonsampling 
errors. Nonsampling errors include 
reporting and processing errors, as well 
as biases due to nonresponse and 
incomplete response. The magnitude of 
the nonsampling errors cannot be 
computed. However, these errors were 
kept to a minimum by procedures built 
into the operation of the survey. To 
eliminate ambiguities and encourage 
uniform reporting, attention was given 
to the phrasing of questions, terms, and 
definitions. Also, most data items and 
survey procedures were pretested. 
Quality control procedures and 
consistency and edit checks reduced 
errors in data coding and processing. 
The error rate (which includes coding 
and keying errors) ranged from 0.0 to 
1.5 for both surveys. 
Adjustments for item nonresponse 
include the following: Missing data for 
several of the items mentioned in this report were imputed by randomly 
assigning a value from a PRF with 
similar characteristics. These items 
include patient’s birth date (used to 
determine age), sex, race, and ethnicity. 
In the NAMCS, imputations were based 
on physician specialty, geographic 
region, and 3-digit ICD-9-CM code for 
primary diagnosis. In the NHAMCS, 
imputations for ED data were based on 
ED size, geographic region, immediacy 
with which patient should be seen, and 
3-digit ICD-9-CM code for primary 
diagnosis. For OPD data, imputations 
were based on geographic region, OPD 
size by clinic, and 3-digit ICD-9-CM 
code for primary diagnosis. Beginning 
in 2004, the imputation for ethnicity 
was revised to take into account state 
rather than region. 
Tests of Significance 
In this report, the determination of 
statistical inference is based on the X2 
test and the two-tailed t-test. The 
Bonferroni inequality was used to 
establish the critical value for 
statistically significant differences (0.05 
level of significance) based on the 
number of possible comparisons within 
a particular variable (or combination of 
variables) of interest. Terms relating to 
differences such as ‘‘greater than’’ or 
‘‘less than’’ indicate that the difference 
is statistically significant. A lack of 
comment regarding the difference 
between any two estimates does not 
mean that the difference was tested and 
found to be not significant. Chi-square 
tests were performed using the 
SUDAAN routine PROC CROSSTAB, 
which takes into account the complex 
sample designs used in the NAMCS and 
NHAMCS. 
A weighted least-squares regression 
analysis was used to determine the 
significance of the relationship between 
age and drug mention rates. In this 
modified least-squares regression, each 
estimate is weighted by the inverse of 
the standard error (22). 
Published and Flagged 
Estimates 
Estimates are not presented unless a 
reasonable assumption regarding their probability distributions is possible on 
the basis of the Central Limit Theorem. 
The Central Limit Theorem states that, 
given a sufficiently large sample size, 
the sample estimate approximates the 
population estimate and, upon repeated 
sampling, its distribution would be 
approximately normal. 
In this report, estimates are not 
presented if they are based on fewer 
than 30 cases in the sample data; only 
an asterisk (*) appears in the tables. 
Estimates based on 30 or more cases are 
asterisked only if the RSE of the 
estimate exceeds 30 percent. 
In addition, estimates in this report 
have been rounded to the nearest 
thousand. Consequently, summed figures 
may not always add to totals. Rates and 
percentages were calculated from 
original unrounded figures and do not 
necessarily agree with percentages 
calculated from rounded data. 
Physician specialty groupings 
Information on physician specialty 
is obtained from the American Medical 
Association (AMA) and the American 
Osteopathic Association (AOA) as part 
of the initial sampling process and is 
verified with the physician at the time 
of the induction interview. For 
tabulation purposes, doctors of 
osteopathy are grouped with doctors of 
medicine according to their self-
designated practice specialty. 
In this report, office visit data are 
divided into three settings, according to 
the self-designated practice specialty of 
the sampled physician. These data are 
presented in terms of visits to the 
offices of primary care physicians, 
surgical specialists, and medical 
specialists, using a classification 
suggested by the AMA (18). Table I 
shows the specialties used to define 
each category. 
Race and ethnicity 
The 2003–04 NAMCS and 
NHAMCS collected race data according 
to standards issued by the Office of 
Management and Budget in 1999 to 
promote comparability of data among 
federal data sources and so that more 
than one race could be recorded per 
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Table I. Reclassification of physician specialty for use with National Ambulatory Medical Care Survey data 
Physician specialty group	 Physician specialty 
Primary care specialties . . . . . . . 	 Family  practice,  geriatric  medicine  (family  practice),  sports medicine (family practice), general practice, internal medicine, 
internal medicine (pediatrics), adolescent medicine (internal medicine), geriatric medicine (internal medicine), adolescent 
medicine, pediatrics, pediatric sports medicine, gynecology, maternal and fetal medicine, obstetrics and gynecology, 
obstetrics. 
Surgical specialties . . . . . . . . . 	 General surgery, gynecological oncology, critical care medicine (obstetrics and gynecology), hand surgery (orthopedic 
surgery), adult reconstructive orthopedics, foot and ankle orthopedics, musculoskeletal oncology, pediatric orthopedics, 
orthopedic surgery, sports medicine (orthopedic surgery), orthopedic surgery of the spine, orthopedic trauma, urology, 
pediatric urology, ophthalmology, pediatric ophthalmology, otology-neurotology, otology, otolaryngology, pediatric 
otolaryngology, abdominal surgery, cardiovascular surgery, colon and rectal surgery, cardiothoracic surgery, craniofacial 
surgery, critical care surgery, dermatologic surgery, facial plastic surgery, head and neck surgery, hand surgery (plastic 
surgery), hand surgery (surgery), critical care (neurological surgery), neurological surgery, pediatric surgery (neurology), 
pediatric cardiothoracic surgery, pediatric surgery, plastic surgery, surgical oncology, thoracic surgery, transplant surgery, 
traumatic surgery, vascular surgery. 
Medical specialties . . . . . . . . . 	 Critical  care  pediatrics, developmental-behavioral pediatrics, neurodevelopmental disabilities, neonatal-perinatal medicine, 
pediatric allergy, pediatric cardiology, pediatric endocrinology, pediatric infectious diseases, pediatric pulmonology, medical 
toxicology (pediatrics), pediatric emergency medicine, pediatric gastroenterology, pediatric hematology/oncology, pediatric 
nephrology, pediatric rehabilitation medicine, pediatric rheumatology, reproductive endocrinology, cardiovascular diseases, 
dermatology, psychiatry, addiction psychiatry, child psychiatry, forensic psychiatry, psychoanalysis, geriatric psychiatry, 
neurology, child neurology, clinical neurophysiology, neurology (diagnostic radiology), addiction medicine, aerospace medicine, 
allergy, allergy and immunology, allergy and immunology/diagnostic laboratory immunology, cardic electrophysiology, clinical 
genetics, clinical biochemical genetics, clinical cytogenetics, clinical molecular genetics, critical care medicine, dermatological 
immunology/diagnostic laboratory immunology, diabetes, emergency medicine, epidemiology, endocrinology, gastroenterology, 
general preventive medicine, hematology, hepatology, hematology/oncology, infectious diseases, internal medicine/diagnostic 
laboratory immunology, immunology, interventional cardiology, legal medicine, medical management, medical genetics, 
medical toxicology (emergency medicine), medical toxicology (preventive medicine), medical oncology, nephrology, nutrition, 
occupational medicine, osteopathic manipulative medicine, pain medicine, palliative medicine, pediatric emergency medicine 
(emergency medicine), pediatric/diagnostic laboratory immunology, pharmaceutical medicine, public health, public health and 
general preventive medicine, clinical pharmacology, physical medicine and rehabiliation, pulmonary critical care medicine, 
pulmonary diseases, sports medicine (emergency medicine), sports medicine (physical medicine and rehabilitation), 
rheumatology, spinal cord injury, sleep medicine, undersea medicine, vascular medicine. person (23). Respondents could check 
multiple categories for each patient from 
these groups: White, Black or African 
American, Asian, Native Hawaiian or 
other Pacific Islander, and American 
Indian or Alaska Native. Estimates for 
specific race categories reflect visits 
where only a single race was reported. 
For this report, estimates for the six race 
categories (White, Black or African 
American, Asian, Native Hawaiian or 
other Pacific Islander, American Indian 
or Alaska Native, and persons of 
multiple race) are presented in Tables 2 
and 3, while data for some of these race 
groups are presented in Figure 3 and 
Table 11. Data for all six race groups 
are not shown in Figure 3 and Table 11 
because of small sample sizes. Because 
of the difference between single- and 
multiple-race reporting, race-specific 
estimates prior to 1999 are not strictly 
comparable with those from 1999 and 
subsequent years, when this method of 
collecting race data was implemented in 
NAMCS and NHAMCS. However, from 
1999 to the present, only a small 
proportion of records had multiple races 
indicated. Race and Hispanic origin are 
collected separately in NAMCS and 
NHAMCS in accordance with OMB 
standards. Consequently, all race 
categories include visits by persons of 
Hispanic and not Hispanic origin. 
Persons of Hispanic origin may be of 
any race. 
Population Figures and Rate 
Calculation 
The population figures used in 
calculating 2003–04 visit rates by age, 
sex, race, ethnicity, geographic region, 
MSA status, and insurance status are 
shown in Tables II and III. The 
estimates of age, sex, race, ethnicity, 
and geographic region reflect Census 
2000–based postcensal estimates of the 
civilian noninstitutional population of 
the United States. They are special 
tabulations developed by the Population 
Division, U.S. Census Bureau, from the 
July 1, 2003, and July 1, 2004, set of 
state population estimates. Population 
estimates of MSA status and insurance 
status are based on data from the 2003 
and 2004 National Health Interview Surveys, National Center for Health 
Statistics (NCHS), which also reflect the 
civilian noninstitutional population of 
the United States. NHIS estimates for 
2003 and 2004 were developed using 
Census 2000–based data. All population 
estimates shown are 2-year averages for 
2003 and 2004. 
Changes to Ambulatory Care 
Drug Database and Therapeutic 
Class of Drugs 
Since drug data were first collected 
in 1980, NCHS has provided drug 
characteristics, including therapeutic 
class of drug based on the National 
Drug Code Directory (12), for each drug 
entered on the Patient Record form 
(PRF). Through 2001, only a single 
therapeutic class was included for each 
drug, although drugs may have multiple 
therapeutic classes, and it was not 
necessarily the case that the class listed 
for a particular drug was also the same 
as its intended therapeutic purpose at the 
medical visit. Because of the 
complexities involved with assigning 
therapeutic classes for drugs, the 
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Table II. Population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and National Hospital 
Ambulatory Medical Care Survey, by age, race, sex, and ethnicity: United States, 2003–04 
All Under 15 15–24 25–44 45–64 65–74 75 years 
Characteristic ages years years years years years and over 
Sex Population estimate1 
All races . . . . . . . . . . . . . . . . . . . . . . .  286,947,862 60,728,632 40,369,442 82,178,384 69,205,345 18,156,364 16,309,696 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  140,207,808 31,067,772 20,367,117 40,591,327 33,573,892 8,276,136 6,331,565 
Female  . . . . . . . . . . . . . . . . . . . . . . .  146,740,054 29,660,861 20,002,325 41,587,057 35,631,453 9,880,228 9,978,131 
Race 
White  . . . . . . . . . . . . . . . . . . . . . . . . .  231,403,767 46,394,226 31,477,464 65,550,953 57,805,580 15,649,327 14,526,219 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  114,009,790 23,790,255 16,018,126 32,926,785 28,379,706 7,211,861 5,683,059 
Female  . . . . . . . . . . . . . . . . . . . . . . .  117,393,977 22,603,971 15,459,338 32,624,168 29,425,875 8,437,466 8,843,160 
Black  or  African  American  . . . . . . . . . . . . .  35,925,710 9,422,169 5,851,792 10,338,647 7,441,684 1,661,432 1,209,987 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  16,655,223 4,778,919 2,822,881 4,610,956 3,338,062 686,668 417,738 
Female  . . . . . . . . . . . . . . . . . . . . . . .  19,270,487 4,643,250 3,028,911 5,727,692 4,103,622 974,764 792,249 
American Indian or Alaska Native . . . . . . . .  2,751,939 709,761 498,565 820,285 551,280 105,277 66,773 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  1,362,563 360,245 251,991 409,156 266,089 48,539 26,545 
Female  . . . . . . . . . . . . . . . . . . . . . . .  1,389,376 349,516 246,575 411,129 285,191 56,738 40,228 
Asian  . . . . . . . . . . . . . . . . . . . . . . . . .  12,053,839 2,346,471 1,674,587 4,318,682 2,705,796 600,992 407,313 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  5,821,792 1,195,789 845,725 2,091,077 1,257,866 265,448 165,889 
Female  . . . . . . . . . . . . . . . . . . . . . . .  6,232,047 1,150,682 828,862 2,227,605 1,447,930 335,544 241,424 
Native Hawaiian or other Pacific Islander . . . 491,382 123,083 88,609 163,095 89,004 17,338 10,254 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  247,233 62,948 45,180 82,661 44,025 8,216 4,205 
Female  . . . . . . . . . . . . . . . . . . . . . . .  244,149 60,136 43,429 80,435 44,979 9,122 6,049 
More  than  one  race  reported  . . . . . . . . . . .  4,321,227 1,732,924 778,426 986,723 612,003 122,000 89,152 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  2,111,208  879,617 383,216 470,694 288,146 55,405 34,131 
Female  . . . . . . . . . . . . . . . . . . . . . . .  2,210,019 853,307 395,211 516,029 323,857 66,595 55,021 
Ethnicity 
Hispanic or Latino. . . . . . . . . . . . . . . . . .  40,089,664 11,832,596 6,887,270 13,271,387 6,030,483 1,234,804 833,124 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  20,526,263 6,047,788 3,635,107 7,018,747 2,949,268 547,280 328,074 
Female  . . . . . . . . . . . . . . . . . . . . . . .  19,563,402 5,784,809 3,252,163 6,252,640 3,081,216 687,524 505,051 
Not Hispanic or Latino . . . . . . . . . . . . . . .  246,858,198 48,896,036 33,482,172 68,906,997 63,174,862 16,921,560 15,476,572 
Male  . . . . . . . . . . . . . . . . . . . . . . . .  119,681,546 25,019,984 16,732,010 33,572,580 30,624,625 7,728,856 6,003,492 
Female  . . . . . . . . . . . . . . . . . . . . . . .  127,176,652 23,876,052 16,750,162 35,334,417 32,550,238 9,192,704 9,473,080 
1Estimates are of the civilian noninstitutionalized population and are from special tabulations developed by the Population Division, U.S. Census Bureau, using July 1, 2003, and July 1, 2004, sets of 
state population estimates and reflect Census 2000 data. decision was made, beginning with the 
2002 data release, to include up to three 
therapeutic classes for each drug entry 
on the PRF. 
For this report, the drug 
characteristics updated for use with 
2004 data were applied to 1993–94 data 
as well so that comparisons could be 
made between the two time periods, 
1993–94 and 2003–04. As a 
consequence, the totals shown in Table 6 
exceed the actual sum of drugs 
provided, prescribed, or continued at 
ambulatory care visits since each drug 
may be assigned as many as three 
therapeutic classes. 
Researchers doing trend analysis 
with NAMCS and NHAMCS drug data 
are advised to download the Drug 
Characteristics file, available at the Ambulatory Health Care Data website 
(http://www.cdc.gov/nchs/namcs.htm). 
The characteristics from this file can be 
applied by matching drug codes to 
previous years of data to get the most 
accurate results when doing analysis of 
drug trends. A file layout and sample 
SAS code for applying drug 
characteristics from the file to previous 
years of public use data is also available 
for downloading. 
The current Drug Characteristics 
file contains a number of updates and 
revisions. Over the last few years, many 
drugs had ingredient lists reviewed, and 
non active ingredients were removed. 
Duplicate codes caused by misspellings 
or other variant entries were eliminated, 
and incorrect codes (for example, for 
non medications) were removed. The Drug Characteristics file is updated 
annually, and is generally available 
following the release of public-use files 
for the survey year in question. 
Tables 8, 9, and 12 which show 
ranked generic substances occurring in 
drugs provided, prescribed, or continued 
at ambulatory care visits, utilize a 
format for generic substances that is 
slightly modified from the results one 
would get using the current Drug 
Characteristics file. In the ambulatory 
care drug database (and the Drug 
Characteristics file), certain substances 
can appear in both generic and salt 
forms, such as albuterol and albuterol 
sulfate, or in forms such as hydrocodone 
and hydrocodone bitartrate. With the 
advent of the 2002 Drug Characteristics 
file, the drug database staff also 
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Table III. Population estimates used in computing annual visit rates for the National 
Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, 
by geographic region, metropolitan statistical area status, and insurance status: 
United States, 2003–04 
Population 
Characteristic estimate 
Geographic region1 
Northeast . . . . . . . . . . . . . . . . . . . . . . . . .  53,663,348

Midwest  . . . . . . . . . . . . . . . . . . . . . . . . . .  64,541,714

South. . . . . . . . . . . . . . . . . . . . . . . . . . . .  102,917,535

West  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65,825,265

MSA status2 
MSA  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  240,805,071 
Non-MSA  . . . . . . . . . . . . . . . . . . . . . . . . .  46,142,791 
Insurance status3 
Private insurance . . . . . . . . . . . . . . . . . . . .  193,071,855

Medicare. . . . . . . . . . . . . . . . . . . . . . . . . .  35,595,073

Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . .  30,284,147

Uninsured . . . . . . . . . . . . . . . . . . . . . . . . .  41,496,808

1Estimates are of the civilian noninstitutionalized population of the United States and are from special tabulations developed by 
the Population Division, U.S. Census Bureau, using July 1, 2003, and July 1, 2004, sets of state population estimates and reflect 
Census 2000 data. 
2MSA is metropolitan statistical area. Estimates are based on data from the 2003 and 2004 National Health Interview Surveys, 
NCHS, adjusted to the U.S. Census Bureau definition of core-based statistical areas as of December 2003. 
3Estimates are from the 2003 and 2004 National Health Interview Surveys, NCHS, adjusted to Census 2000–based population 
estimates. formulated a list of generic codes which 
collapses different formulations for 
generic substances into aggregate 
categories. Therefore, in Tables 8, 9, and 
12, albuterol is displayed but actually 
reflects a combination of albuterol and 
albuterol sulfate in the original survey 
data. The aggregated format for generic 
substances is also available at the 
Ambulatory Health Care Data website. 
For more information, contact the 
Ambulatory Care Statistics Branch. 
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Definition of Terms 
Drug mention—A drug mention is 
the physician’s entry on the Patient 
Record form of a pharmaceutical 
agent—by any route of administration— 
for prevention, diagnosis, or treatment. 
Generic as well as brand-name drugs are 
included, as are nonprescription and 
prescription drugs. Along with all new 
drugs, the physician also records 
continued medications if the patient was 
specifically instructed during the visit to 
continue the medication. Physicians may 
report up to eight medications per visit. 
Drug mention rate—For this report, 
a drug mention rate is the number of 
drug mentions per 100 office visits. It 
allows one to compare prescribing rates 
while holding the number of visits 
constant. 
Drug visit—A drug visit is a visit at 
which medication was prescribed or 
provided by the physician. 
Emergency department (ED)—An 
ED is a hospital facility that provides 
unscheduled outpatient services to 
patients whose conditions require 
immediate care and that is staffed 24 
hours a day. If an ED provided 
emergency services in different areas of 
the hospital, all of these areas were 
selected with certainty into the sample. 
Off-site emergency departments that are 
open less than 24 hours are included if 
staffed by the hospital’s emergency 
department. 
Emergency service area—An 
emergency service area is the smallest 
administrative unit of an ED where 
separate patient statistics are kept. It 
may be located on hospital grounds or 
operated off site by the hospital. 
Federal control status— Federal 
control status refers to the classification 
of a substance according to the 
Controlled Substances Act (CSA), Title 
II of the Comprehensive Drug Abuse 
Prevention and Control Act of 1970. 
CSA places all substances that are 
regulated under existing federal law into 
one of five schedules. This placement is 
based on the substance’s medicinal value, harmfulness, and potential for 
abuse or addiction. The schedules are as 
follows: 
+ Schedule I: (A) The drug or 
other substance has a high potential for 
abuse. (B) The drug or other substance 
has no currently accepted medical use in 
treatment in the United States. (C) There 
is a lack of accepted safety for use of 
the drug or other substance under 
medical supervision. 
+ Schedule II: (A) The drug or 
other substance has a high potential for 
abuse. (B) The drug or other substance 
has a currently accepted use in treatment 
in the United States or a currently 
accepted medical use with severe 
restrictions. (C) Abuse of the drug or 
other substance may lead to severe 
psychological or physical dependence. 
+ Schedule III: (A) The drug or 
other substance has a potential for abuse 
less than the drugs or other substances 
on schedules I and II. (B) The drug or 
other substance has a currently accepted 
medical use in treatment in the United 
States. (C) Abuse of the drug or other 
substance may lead to moderate or low 
physical dependence or high 
psychological dependence. 
+ Schedule IV: (A) The drug or 
other substance has a low potential for 
abuse relative to the drugs or other 
substances in schedule III. (B) The drug 
or other substance has a currently 
accepted medical use in treatment in the 
United States. (C) Abuse of the drug or 
other substance may lead to limited 
physical dependence or psychological 
dependence relative to the drugs or 
other substances in schedule III. 
+ Schedule V: (A) The drug or 
other substance has a low potential for 
abuse relative to the drugs or other 
substances in schedule IV. (B) The drug 
or other substance has a currently 
accepted medical use in treatment in the 
United States. (C) Abuse of the drug or 
other substance may lead to limited 
physical dependence or psychological 
dependence relative to the drugs or 
other substances in schedule IV. 
Geographic region—The 50 states 
and the District of Columbia are 
grouped for statistical purposes by the 
U.S. Census Bureau into the following 
four geographic regions: Region States included 
Northeast Maine, New Hampshire, 
Vermont, Massachusetts, 
Rhode Island, Connecticut, 
New York, New Jersey, and 
Pennsylvania; 
Midwest Ohio, Indiana, Illinois, 
Michigan, Wisconsin, 
Minnesota, Iowa, Missouri, 
North Dakota, South Dakota, 
Nebraska, and Kansas; 
South Delaware, Maryland, District 
of Columbia, Virginia, West 
Virginia, North Carolina, 
South Carolina, Georgia, 
Florida, Kentucky, Alabama, 
Mississippi, Arkansas, 
Louisiana, Oklahoma, and 
Texas; 
West Montana, Idaho, Wyoming, 
Colorado, New Mexico, 
Arizona, Utah, Nevada, 
Washington, Oregon, 
California, Alaska, and 
Hawaii. 
Hospital —A hospital is eligible for 
inclusion in NHAMCS if it has an 
average length of stay for all patients of 
less than 30 days (short-stay) or if it has 
a specialty of general (medical or 
surgical) or children’s general. The 
survey excludes federal hospitals, 
hospital units of institutions, and 
hospitals with less than six beds staffed 
for patient use. 
Metropolitan status—Providers are 
classified by their location in a 
metropolitan statistical area or 
nonmetropolitan statistical area as 
follows: 
+	 Metropolitan statistical area 
(MSA)—As defined by the U.S. 
Office of Management and 
Budget, the definition of an 
individual MSA involves two 
considerations: first, a city or 
cities of specified population 
that constitute the central city 
and identify the county in which 
it is located as the central 
county; second, economic and 
social relationships with 
‘‘contiguous’’ counties that are 
metropolitan in character so that 
the periphery of the specific 
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determined. MSAs may cross 
state lines. In New England, 
MSAs consist of cities and 
towns rather than counties. 
+	 Non-MSA—Non-MSA areas are 
those not defined as MSAs. 
Office—An office is the space 
identified by a physician as a location 
for his or her ambulatory practice. 
Offices customarily include consultation, 
examination, or treatment spaces that 
patients associate with the particular 
physician. 
Office-based physician—A 
physician is a duly licensed doctor of 
medicine (M.D.) or doctor of osteopathy 
(D.O.) who is currently in office-based 
practice and who spends some time 
caring for ambulatory patients. Excluded 
from NAMCS are physicians who are 
hospital based; who specialize in 
anesthesiology, pathology, or radiology; 
who are federally employed; who treat 
only institutionalized patients; or who 
are employed full time by an institution 
and spend no time seeing ambulatory 
patients. 
Outpatient department (OPD)—An 
OPD is a hospital facility where 
nonurgent and ambulatory medical care 
is provided under the supervision of a 
physician. 
Population rate—The population 
rate is a basic measure of service 
utilization for event-based surveys. In 
this report, the numerator is the number 
of occurrences of therapeutic classes of 
drugs prescribed, provided, or continued 
at ambulatory care visits and the 
denominator is the corresponding U.S. 
population estimate for those who could 
have made the visits. The interpretation 
is that for every person in the 
population, there are x occurrences of 
therapeutic classes of drugs prescribed, 
provided, or continued at ambulatory 
care visits. It does not mean that x 
percentage of the population was 
prescribed drugs of particular classes at 
ambulatory care visits because some 
persons in the population make no visits 
while others make multiple visits within 
a given year, and some persons make 
visits at which no drugs are prescribed. 
The population rate is best used to 
compare amounts of utilization across various subgroups of interest such as 
age, race, or geographic region (e.g., the 
rate of antihistamine drug classes for 
drugs reported at U.S. ambulatory care 
visits in 2003–04 was 339.2 per 1,000 
females and 211.6 per 1,000 males). 
Prescription status—Prescription 
status refers to whether a drug is 
available by prescription only or as an 
over-the-counter (nonprescription) 
preparation. Drugs that are available as 
either prescription or over-the-counter 
preparations (for example, ibuprofen) 
are classed in an ‘‘undetermined’’ 
category in NAMCS and NHAMCS. 
Primary expected source of 
payment—The primary expected source 
of payment is the source that, to the best 
of the provider’s knowledge, describes 
how charges incurred during this visit 
will be paid. 
+	 Private insurance—This 
category includes charges paid 
in  part or in full by a private  
insurance company, health 
maintenance organization 
(HMO) plan, or other 
prepayment plan, including 
independent practice associations 
(IPAs) and preferred provider 
organizations (PPOs). 
+	 Medicare—This category 
includes charges paid in part or 
in full by a Medicare plan, 
including payments made 
directly to the hospital as well 
as payments to the patient. 
+	 Medicaid/SCHIP—This category 
includes charges paid in part or 
in full by Medicaid or a State 
Children’s Health Insurance Plan 
(SCHIP), including payments 
made directly to the hospital as 
well as payments to the patient. 
SCHIP, enacted as part of the 
Balanced Budget Act of 1997, 
gave states the opportunity to 
provide free or low-cost 
insurance coverage to 
low-income children not 
otherwise eligible to be covered 
by Medicaid. States began 
enrolling children in 1998 using 
Medicaid or state-specific 
programs separate from 
Medicaid, or both. By 2000, all states had implemented their 
SCHIP programs. 
+	 Worker’s compensation—This 
category includes programs 
designed to enable employees 
injured on the job to receive 
financial compensation 
regardless of fault. 
+	 Self-pay—This category includes 
charges that are billed directly to 
the patient and will not be 
reimbursed by a third party. 
Self-pay does not include 
prepaid plans for which a 
copayment is charged. 
+	 No charge—No fee is charged 
for these visits. This category 
does not include visits paid for 
as part of a total care package 
(e.g., postoperative visits 
included in a surgical fee, 
pregnancy visits for which a flat 
fee was charged, and HMO and 
prepaid systems). 
+	 Other—This category includes 
other sources of payment not in 
the preceding categories, including 
charges paid under CHAMPUS, 
state and local governments, 
private charitable organizations, 
and other liability insurance. 
+	 Unknown—This category 
includes cases for which none of 
the previous sources of payment 
categories was checked. 
For this report, visits were designated 
‘‘uninsured’’ if either self-pay or no charge 
was indicated. ‘‘Other’’ sources included 
worker’s compensation, other, and 
unknown. 
Visit —For NAMCS, a visit is a 
direct personal exchange between an 
ambulatory patient and a physician or a 
staff member working under the 
physician’s supervision for the purpose of 
seeking care and rendering personal health 
services. The NAMCS sample excludes 
visits where medical care was not 
provided (e.g., visits made to drop off 
specimens, pay bills, make appointments, 
and walkouts). For NHAMCS, a visit is a 
direct, personal exchange between a 
patient and a physician or other health 
care provider working under the 
physician’s supervision for the purpose of 
seeking care and receiving personal health 
services. 
Page 38 [ Series 13, No. 163 
Appendix III

Survey Instruments 
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Vital and Health Statistics 
series descriptions 
SERIES 1.	 Programs and Collection Procedures—These reports 
describe the data collection programs of the National Center 
for Health Statistics. They include descriptions of the methods 
used to collect and process the data, definitions, and other 
material necessary for understanding the data. 
SERIES 2.	 Data Evaluation and Methods Research—These reports 
are studies of new statistical methods and include analytical 
techniques, objective evaluations of reliability of collected 
data, and contributions to statistical theory. These studies 
also include experimental tests of new survey methods and 
comparisons of U.S. methodology with those of other 
countries. 
SERIES 3.	 Analytical and Epidemiological Studies—These reports 
present analytical or interpretive studies based on vital and 
health statistics. These reports carry the analyses further than 
the expository types of reports in the other series. 
SERIES 4.	 Documents and Committee Reports—These are final 
reports of major committees concerned with vital and health 
statistics and documents such as recommended model vital 
registration laws and revised birth and death certificates. 
SERIES 5.	 International Vital and Health Statistics Reports—These 
reports are analytical or descriptive reports that compare U.S. 
vital and health statistics with those of other countries or 
present other international data of relevance to the health 
statistics system of the United States. 
SERIES 6.	 Cognition and Survey Measurement—These reports are 
from the National Laboratory for Collaborative Research in 
Cognition and Survey Measurement. They use methods of 
cognitive science to design, evaluate, and test survey 
instruments. 
SERIES 10.	 Data From the National Health Interview Survey—These 
reports contain statistics on illness; unintentional injuries; 
disability; use of hospital, medical, and other health services; 
and a wide range of special current health topics covering 
many aspects of health behaviors, health status, and health 
care utilization. They are based on data collected in a 
continuing national household interview survey. 
SERIES 11.	 Data From the National Health Examination Survey, the 
National Health and Nutrition Examination Surveys, and 
the Hispanic Health and Nutrition Examination Survey— 
Data from direct examination, testing, and measurement on 
representative samples of the civilian noninstitutionalized 
population provide the basis for (1) medically defined total 
prevalence of specific diseases or conditions in the United 
States and the distributions of the population with respect to 
physical, physiological, and psychological characteristics, and 
(2) analyses of trends and relationships among various 
measurements and between survey periods. 
SERIES 12.	 Data From the Institutionalized Population Surveys— 
Discontinued in 1975. Reports from these surveys are 
included in Series 13. 
SERIES 13.	 Data From the National Health Care Survey—These 
reports contain statistics on health resources and the public’s 
use of health care resources including ambulatory, hospital, 
and long-term care services based on data collected directly 
from health care providers and provider records. 
SERIES 14.	 Data on Health Resources: Manpower and Facilities— 
Discontinued in 1990. Reports on the numbers, geographic 
distribution, and characteristics of health resources are now 
included in Series 13. 
SERIES 15.	 Data From Special Surveys—These reports contain 
statistics on health and health-related topics collected in 
special surveys that are not part of the continuing data 
systems of the National Center for Health Statistics. 
SERIES 16.	 Compilations of Advance Data From Vital and Health 
Statistics—Advance Data Reports provide early release of 
information from the National Center for Health Statistics’ 
health and demographic surveys. They are compiled in the 
order in which they are published. Some of these releases 
may be followed by detailed reports in Series 10–13. 
SERIES 20.	 Data on Mortality—These reports contain statistics on 
mortality that are not included in regular, annual, or monthly 
reports. Special analyses by cause of death, age, other 
demographic variables, and geographic and trend analyses 
are included. 
SERIES 21.	 Data on Natality, Marriage, and Divorce—These reports 
contain statistics on natality, marriage, and divorce that are 
not included in regular, annual, or monthly reports. Special 
analyses by health and demographic variables and 
geographic and trend analyses are included. 
SERIES 22.	 Data From the National Mortality and Natality Surveys— 
Discontinued in 1975. Reports from these sample surveys, 
based on vital records, are now published in Series 20 or 21. 
SERIES 23.	 Data From the National Survey of Family Growth—These 
reports contain statistics on factors that affect birth rates, 
including contraception, infertility, cohabitation, marriage, 
divorce, and remarriage; adoption; use of medical care for 
family planning and infertility; and related maternal and infant 
health topics. These statistics are based on national surveys 
of women of childbearing age. 
SERIES 24.	 Compilations of Data on Natality, Mortality, Marriage, and 
Divorce—These include advance reports of births, deaths, 
marriages, and divorces based on final data from the National 
Vital Statistics System that were published as National Vital 
Statistics Reports (NVSR), formerly Monthly Vital Statistics 
Report. These reports provide highlights and summaries of 
detailed data subsequently published in Vital Statistics of the 
United States. Other special reports published here provide 
selected findings based on final data from the National Vital 
Statistics System and may be followed by detailed reports in 
Series 20 or 21. 
For answers to questions about this report or for a list of reports published 
in these series, contact: 
Information Dissemination Staff 
National Center for Health Statistics 
Centers for Disease Control and Prevention 
3311 Toledo Road, Room 5412 
Hyattsville, MD 20782 
1-866-441-6247

E-mail: nchsquery@cdc.gov

Internet: www.cdc.gov/nchs
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